

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email editorial.bmjopen@bmj.com

BMJ Open

Examining the effects of enhanced provider-patient communication on post-operative pain; Protocol of a Randomized Controlled Trial performed in daily clinical care

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-015505
Article Type:	Protocol
Date Submitted by the Author:	09-Dec-2016
Complete List of Authors:	van Vliet, Liesbeth; Nederlands Instituut voor Onderzoek van de Gezondheidszorg, Communication van Dulmen, Sandra; NIVEL, Thiel, B; Onze Lieve Vrouwe Gasthuis, Department of Anaesthesiology van Deelen, G; Onze Lieve Vrouwe Gasthuis, Department of ENT Immerzeel, S; Nederlands Instituut voor Onderzoek van de Gezondheidszorg, Communication Godfried, M; Onze Lieve Vrouwe Gasthuis, Department of Anesthesiology Bensing, Jozien; NIVEL, Netherlands Institute for Health Services Res
Primary Subject Heading:	Communication
Secondary Subject Heading:	Anaesthesia
Keywords:	communication, placebo-effects, Pain management < ANAESTHETICS, tonsillectomy, randomized controlled trial

SCHOLARONE™
Manuscripts

only

1

Title page

Title: Examining the effects of enhanced provider-patient communication on post-operative pain; Protocol of a Randomized Controlled Trial performed in daily clinical care.

Van Vliet, van Dulmen, Thiel, van Deelen, Immerzeel, Godfried, Bensing

Corresponding author:

Dr Liesbeth M van Vliet

NIVEL (Netherlands institute for health services research), Department of Communication

P.O.Box 1568

3500 BN Utrecht

The Netherlands

Email: l.vanvliet@nivel.nl

Telephone number: 0031 30 27 29 632

Prof. dr. Sandra van Dulmen

NIVEL, Department of Communication

Utrecht, the Netherlands

Email: S.vandulmen@nivel.nl

Bram Thiel MSc

OLVG Hospital, Department of Anesthesiology

Amsterdam, the Netherlands

Email: B.Thiel@olvg.nl

Dr G. W. van Deelen

OLVG Hospital, Department of ENT

Amsterdam, the Netherlands

Email: G.W.vanDeelen@olvg.nl

Protocol article Clinical study Spinoza V1.0 05-12-2016 clean version

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

2

Stephanie Immerzeel MSc
NIVEL, Department of Communication
Utrecht, the Netherlands
Email: S.Immerzeel@nivel.nl

Dr Marc B Godfried
OLVG Hospital, Department of Aneesthesiology
Amsterdam, the Netherlands
Email: M.B.Godfried@olvg.nl

Prof. dr. Jozien M Bensing
NIVEL, Department of Communication
Utrecht, the Netherlands
Email: j.bensing@nivel.nl

Word count: 4856

Number of Figures: 1

Number of Tables: 1

Number of References: 25

Key words: Communication, placebo-effects, pain management, tonsillectomy,
randomized controlled trial

3

Abstract

Introduction: Placebo effects (true biopsychological effects not attributable to the active ingredients of medical technical interventions) can be attributed to several mechanisms, such as expectancy manipulation and empathy manipulation elicited by a provider's communication. So far, effects have primarily been shown in laboratory settings. The aim of this study is to determine the separate and combined effects of expectancy manipulation and empathy manipulation during pre- and post-operative tonsillectomy analgesia care on clinical adult patients' outcomes.

Methods and analysis: Using a two by two randomized controlled trial 128 adult tonsillectomy patients will be randomly assigned to one out of four conditions differing in the level of expectancy manipulation (standard versus enhanced) and empathy manipulation (standard versus enhanced). Daycare ward nurses are trained to deliver the intervention, while patients are treated via the standard analgesia protocol and hospital routines. The primary outcome, perceived pain, is measured via hospital routine by a Numeric Rating Scale, and additional pre-, peri- and post-hospitalization questionnaires are completed (until day 3, i.e. 2 days after the operation). The manipulation is checked using audio-recordings of nurse-patient interactions.

Ethics and dissemination: Although communication is manipulated, the manipulations do not cross norms or values of acceptable behavior. Standard medical care is provided. The ethical committee of the UMC Utrecht and the local OLVG hospital committee approved the study. Results will be published via (inter)national peer-reviewed journals and a lay publication.

Registration details: NTR5994 (Dutch Trial Register)

Strengths:

- This study is a RCT on the (placebo) effects of communication on top of standard medical care, building the evidence-base of communication.

Limitations:

- The success of the intervention will depend on the ability of nurses to carry out the different communication styles successfully

INTRODUCTION

In clinical care, patients' outcomes are not only influenced by the active ingredients of drugs or other medical technical interventions, but also by the context in which care is delivered. Such biopsychosocial effects on patients' outcomes that are not attributable to the active ingredients of treatments or interventions are called 'non-specific' or 'placebo-effects'[1 2]. They are real and robust, occurring on top of natural history and regression to the mean[3], and can be observed alongside 'sham-treatments' as well as 'real treatments'.

Several mechanisms underlie the generation of placebo-effects on patient outcomes such as pain[4]. A well-understood mechanism is the manipulation of expectations. According to a recent systematic review of our research group, manipulating patients' expectations seems capable of influencing clinical patients' pain perceptions[5]. For example, the verbal suggestion that a drug is an active pain killer is more effective than receiving the same dosage medication without such a suggestion[6]. A less-well understood mechanism is the communication of empathy in health care professional-patient encounters. Only few scholars have pointed out the potential role of the professional-patient relationship in explaining placebo-effects[7-9]. In our systematic review, we found that empathy had a less strong effect on pain compared to expectations[5]; but studies used different empathy operationalization and empathy was often manipulated together with other elements of the clinical encounter, making it difficult to draw strong conclusions from empathy[5].

When looking at these mechanisms, it seems reasonable that health care professionals' communication can influence them, and can thus produce placebo-effects. Until recently, however, the entities of communication and placebo-effects have hardly been integrated[9]. Communication is traditionally associated with 'art, not science' and placebos with 'evidence-based medicine' in which their effects are typically ruled out by the study design of randomized controlled trials (RCTs).

The tide is changing. A landmark-study led by Kaptchuk et al 2008[8] found that placebo-acupuncture delivered with high outcome expectations and an empathic approach led to

5

1
2
3 statistically and clinically significant improvements in the functioning of patients with
4 irritable bowel syndrome compared to placebo-acupuncture delivered without
5 expectations and empathy. The distinct and combined effects of both mechanism, and the
6 effects alongside an active treatment remain, however, unknown from this study.
7
8
9

10
11
12 Our research group has started to unravel the potential separate and combined effects of
13 both expectancy manipulation and empathy manipulation in highly controlled settings.
14 Using scripted video-vignettes and role-play studies, we found that expectancy mainly
15 influences cognitive outcomes (e.g. expected treatment effect) and empathy mainly
16 affective outcomes (e.g. anxiety). The largest positive effects were found when the two
17 elements were combined and a physician raised high expectations meanwhile
18 communicating in a warm, empathic manner[10] (van Osch et al, 2016, *submitted*).
19 However, whether these distinct and combined effects also translate to the clinical setting,
20 alongside an active intervention remains, as yet, an unanswered question.
21
22
23
24
25
26
27
28
29

30 **Study objective**

31
32 This study therefore aims to disentangle the role of communication in eliciting placebo-
33 effects in the clinical setting within the context of standard medical care. More specifically,
34 the objective is to determine the separate and combined effects of expectancy
35 manipulation (standard versus enhanced) and empathy manipulation (standard versus
36 enhanced) during pre- and post-operative tonsillectomy analgesia care on clinical adult
37 patients' outcomes (main outcome measure is pain perception). This will be studied using
38 a 2 by 2 RCT design. By following this approach the evidence base on the effects of
39 expressed outcome expectancy and conveyed empathy will be built in clinical care.
40
41
42
43
44
45
46
47
48

49 Accompanying the study objective, the goals of this study are in subsequent order:

- 50 1. To examine whether adult patients following tonsillectomy in the enhanced
51 outcome expectancy condition will experience less pain (and other outcomes), compared
52 to patients in the standard condition.
53
54
55
56
57
58
59
60

6

2. To examine whether adult patients following tonsillectomy in the enhanced empathy communication condition will experience less pain (and other outcomes) compared to patients in the standard empathy communication condition.
3. To examine the interaction effects of the different levels of outcome expectancy and empathy on adult patients' experiences of pain (and other outcomes).

METHODS AND ANALYSIS

Design and setting

A four-arm (2 by 2 design) single-blind randomized controlled trial will be conducted at the daycare nursing wards on two locations of a Dutch general hospital (OLVG Amsterdam), in which adult tonsillectomy patients are pre- and postoperatively monitored and treated by nurses. Patients will be randomly assigned to one out of 4 arms, which vary in the induction of expectations (standard vs enhanced), and (the level of) nurses' communication of empathy (standard vs enhanced). Depending on the patient's allocation, nurses will express a standard or enhanced outcome expectation of patients' pain, and provide care in a standard or enhanced empathic manner. See figure 1 for the study design. All patients will be treated according to the usual analgesic treatment protocol and daily routine care of the hospital. Recruitment started in August 2016 and will presumably continue until early 2017.

Patients

This study focusses on adult tonsillectomy patients. This population was carefully selected as it is a homogeneous population. These patients are young adults, generally aged 18-35, without complex comorbidity (ASA 1) and lack a history of chronic pain. Moreover, tonsillectomy is generally accepted as a strong confound nociceptive trigger resulting into high levels of postoperative pain that only lasts for a relatively short period of time (1-2 weeks).

Inclusion criteria

7

In order to be eligible to participate in this study, a patient must meet the following criteria:

- Scheduled for tonsillectomy in day care
- ≥ 18 years of age
- Speaking and understanding of the Dutch language
- Having mental capacity

Exclusion criteria

A potential patient who meets the following criteria will be excluded from participation in this study:

At study start (during inclusion process):

- Not scheduled for tonsillectomy in day care
- < 18 years of age
- Not speaking and understanding of the Dutch language
- Lacking mental capacity (cognitive decline, dementia)

During the course of the study:

- Patients who experience a post-operative bleeding will be excluded.
- The health care professionals involved and research team can decide to withdraw a patient from the study for urgent medical reasons (e.g. if patients are not discharged on the day of operation due to complications).

If a patient drops-out, data until exclusion will be included in the analyses unless the patient objects to this (this will be asked upon exclusion).

Sample size

The sample size calculation is based on the primary outcome, i.e. pain. This calculation is based on a previous similar study[6], in which an open versus hidden administration of analgesic showed a difference of 1.2 and a total variance of 2.18. Based on a power of .80 and alpha of .05, and including an interaction-effect (with a within variance of 1.92), this results in a needed sample size of 32 patients per arm and $4 \times 32 = 128$ patients in total.

8

Recruitment

The recruitment of patients occurs in several steps:

- i) Patients are approached for the study while discussing the operation with their consulting ear nose and throat specialist (i.e. ENT doctor). All eligible and interested patients are provided with a Patient Information Folder (PIF) and informed consent form. The PIF omits specific study aims, but mentions that communication will be manipulated. It is stressed that participation is free of choice and will not affect usual medical care.
- ii) During the pre-operative examination, which is mostly conducted within a few days of the ENT consultation, the anaesthesiology clinician asks whether the patient is informed about the study. If not, they will provide them the PIF and consent form. They will ask whether the patient is interested in participation and whether the research team can call the patient to provide them with more information. This response is noted in the electronic record and transferred to the researchers via an (automated) email.
- iii) The research team will call the patient, explain the study in more detail and ask the patient to return the informed consent form.

Patients who are already planned for surgery when the study opens (the normal time between ENT consultation and the operation is 6-8 weeks) will be called by involved health care practitioners (from the ENT/Anaesthesiology department). They are informed about the study via telephone. In case they are interested, their name and telephone number are transferred to the researchers. The researchers will call the patient, and send them an information letter and consent form which participants can return in case they are willing to participate.

Randomization

Upon providing informed consent patients are randomized using a random number generator (1:1:1:1: allocation rate). Assignments will be provided via sequentially numbered opaque sealed envelopes. A secretary not otherwise involved in the study will open the assignment envelopes.

9

1
2
3 After patients are randomized, the research team will inform the health care professionals
4 about their inclusion. They will insert this information in the medical records of the
5 hospital system (EPIC). Moreover, they will inform the day care administrators and key
6 contact persons about the patients that are scheduled in the upcoming week or days and
7 which condition they are randomized to. On the day of admission, the researchers will
8 ensure that all appropriate systems (e.g. the ward lists and the hard copy patient records)
9 are adequately signposted with the patients' condition. We will use color codes for this to
10 avoid unblinding patients. Only one patient per room is included at any time point.
11
12
13
14
15
16
17
18
19

20 **Intervention**

21 The intervention consists of a (protocolled) communication manipulation on top of
22 standard analgesic treatment. Nurses at the day care ward will incorporate an
23 (protocolled) expectancy manipulation (standard versus enhanced) related to the effects
24 of the pain medication and empathy manipulation (standard versus enhanced) into their
25 communication. The communication intervention will be provided during patients' stay at
26 the day care ward (pre- and post-operation, day 1, the daycare wards are open between
27 7AM-6PM and 6.45AM-7PM respectively), and during the nurses' telephone consultation
28 with patients the day post-discharge (day 2).
29
30
31
32
33
34
35
36
37

38 All nurses will receive training to ensure their ability to perform the different
39 communication manipulations. We will make use of a professional trainer and
40 comprehensive training protocol including scripts (i.e. written examples), video-examples,
41 and role-play. Moreover, posters are placed in the communal spaces for nurses with
42 information about the study; e.g. examples of the manipulations and study procedures.
43 Pocket cards with examples of the manipulations are provided.
44
45
46
47
48
49

50 *Expectancy manipulation*

51 In the standard condition nurses do not aim to create the expectation that the pain
52 medication will work very well. They might use sentences such as "The medications
53 attempt to reduce your pain ever so slightly", or "This is your pain medication".
54
55
56
57
58
59
60

10

In the enhanced condition nurses aim to create the expectation that the pain medication will work very well. They might use sentences such as: “The medications I am giving you now will lead to a strong decrease of your pain”, or “This pain medication is known for working very well”.

Empathy manipulation

In the standard condition nurses aim to create a neutral atmosphere which is standard. They will be trained to (amongst other behavior) keep standing when communicating with patients, react with standard empathy to patients’ cues and concerns, not explore concerns in detail, to not express extra interest in the patient as a person, to not pay extra attention to not interrupting patients, and to not make extra eye contact.

In the enhanced condition, nurses aim to create an atmosphere, which is extra warm and extra friendly. They will be trained to (amongst other behavior) introduce themselves properly, sit while communicating with patients, react extra empathically to patients’ cues and concerns (verbal and nonverbal) and take their concerns seriously, to show extra interest in the patient as a person, to not interrupt the patient, and to make adequate eye contact.

It should be noted that the communication manipulation does not cross important norms or values of acceptable behavior and that the psychological integrity of patients will not be harmed. An observational study among clinical postsurgical patients showed that nurse-patient interactions are often subject to interruptions related to other tasks e.g. searching for equipment, answering telephone calls, or being interrupted by other professionals[11]. The interruptions and nurses’ attempts to address competing demands impact on the time and attention spent with patients. It can therefore be assumed that variations in communication are inherently due to clinical encounters. This was also confirmed by field observations conducted by the research team before study start. The aforementioned developed scripts/examples which are used in the training have been commented upon by nurses and researchers in a pilot study to ensure they are realistic

11

1
2
3 and do not trespass ethical boundaries and have been finalized in collaboration with
4 involved clinicians.
5
6
7

8 *Standardizing of communication*

9
10 The communication patients receive from other clinicians involved during their
11 hospitalization (e.g. from the OK team and recovery team) will be standardized as much as
12 possible. Also the communication during the pre-operative ENT and Anaesthesiology visit
13 will be standardized as much as possible. Involved health care professionals will be
14 informed of the study aims and the importance to keep their communication neutral (if
15 possible) (i.e. to not provide extra empathy or raise extra expectations about pain) for
16 included patients. This is feasible, as the ENT and anaesthesiology team are involved in the
17 study, and it is uncommon for patients to ask about pain medication during their time at
18 the OK recovery.
19
20
21
22
23
24
25
26
27

28 *Blinding*

29 Patients will be blinded to the specific study aims and treatment allocation.
30
31 The involved health care personnel cannot be blinded. All health care personnel involved
32 will receive clear and specific instructions about informing and including patients to
33 preserve experimental control. Besides, all interactions within the study between nurses
34 and patients will be audio-recorded to evaluate the fidelity of the communication
35 manipulation.
36
37
38
39
40
41
42

43 **Study procedure**

44 After receiving informed consent, the research team will send a baseline questionnaire to
45 the patient. Completion of this questionnaire will be done at home and will take no more
46 than 20 minutes. Post-surgery (at daycare, day 1) a short (5-minute) questionnaire is
47 administered. As part of routine care, pre- and post- surgery, patients rate their level of
48 pain. At day 2 (the day after discharge) patients will complete another questionnaire
49 about their pain and medication use. At day 3 a last questionnaire will be completed which
50 will take 20 minutes. Patients are given the choice between paper and pencil and online
51 completion of questionnaires.
52
53
54
55
56
57
58
59
60

12

Moreover, the interactions between involved nurses and included patients will be recorded. Nurses will be provided with a portable audio-recording device with microphone. During every visit, the nurses will mention patient's identification number by means of reference, to protect patients' privacy. At day 4 (3 days after discharge) patients will receive a debriefing letter by postal mail which will inform them about the study aims and their assigned condition. If they wish to receive more information they can contact the research team.

Withdrawal of individual patients

Patients can leave the study at any time for any reason if they wish to do so without any consequences. The health care professionals involved and research team can decide to withdraw a patient from the study for urgent medical reasons (e.g. a bleeding after operation). If a patient drops-out, the research team is informed of this. Patients will continue to receive standard medical care and communication.

Informed consent nurses

Nurses involved in the study will be asked to participate as participants using an information sheet and a consent form. They will be asked to complete the consent form and a questionnaire about their background characteristics. We will offer them, at study end, participation in a (accredited) communication training to thank them for their participation in this project.

Outcomes

Main study outcome:

- Pain perception/intensity

As part of routine care, during hospitalization and post-hospitalization patients' pain will be assessed on the basis of a Numeric Rating Scale (NRS) (0-10), ranging from 'no pain' to 'worst imaginable pain' [12 13]. Pain is rated preoperatively at daycare ward, at recovery, postoperatively at daycare ward. On study day 2, one day after discharge, daycare ward

13

nurses will contact the patients by telephone and again assess their pain. On top of this standard routine, pain is assessed at home on day 2 and day 3 (study end).

Secondary study outcome

In the patient questionnaires, the following secondary outcomes will be assessed:

- Pain expectations

Patients' pain expectations are measured using two items (both measured using a self-created VAS scale); i) Patients' pain expectations for the few days following the operation (VAS ranging from 'no pain' to 'the most intense pain imaginable', ranging from 0-10, adapted from Petersen et al., 2014[14]); ii) Patients' expectations of improvement in pain following receiving pain medication (VAS ranging from '0% improvement' (no improvement) to '100% improvement' (most improvement imaginable), adapted from the Credibility and Expectancy Questionnaire (CEQ)[15]. These questions will be assessed post-operatively (during hospitalization).

- Overall benefit of analgesia

The overall benefit of analgesia score (OBAS) will be assessed[16]. The OBAS is a multidimensional 7-item instrument in which patients indicate (on a 0-4 scale, ranging from 'not at all' to 'very much') the level of current pain and distress arising from several symptoms such as itch. The OBAS is measured post-hospitalization (at home) at day 2 and 3 (study end).

- Analgesic dosage

The total dosage of administered analgesics will be assessed during hospital stay and noted in the medical record. The total dosage of administered analgesic at home post-operation will be assessed at day 2 and 3 (study end) by asking patients to indicate which pain medication they use/have used.

- Analgesic request by a patient

Analgesic request will be assessed during hospital stay and noted in the medical record.

- Perceived empathy

Perceived empathy will be determined using the Consultation and Relational Empathy Measure (CARE)[17] in which the term 'doctor' is replaced with 'nurse' and 'consultation' is replaced with 'contact' (10 items, 1-5 scale ranging from 'poor' to 'excellent' (and 'not

14

relevant'), e.g. "How was the nurse at showing care and compassion"). Perceived empathy is measured at day 3 (study end).

- Perceived expectation

We will measure the extent to which participants thought nurses had induced the expectation that medication would be effective to decrease their pain. This will be assessed using a 1-item self-created VAS scale ('no effect at all' to 'a lot of effect', ranging from 0-10). Perceived expectation will be measured at day 3 (study end).

- State anxiety

Patients' level of anxiety will be measured by the Dutch 10-item State measure of the State-Trait Anxiety Inventory (STAI-State)[18](1-4 scale ranging 'not at all' to 'very much'). Patients' anxiety is assessed pre-hospitalization, and at day 3 (study end).

- Mood

Mood will be measured using the Positive and Negative Affect Schedule (PANAS)[19] (20-items, 1-5 scale ranging from 'not at all' to 'very much' e.g. "I am excited" or "I am upset"). Mood is measured pre-hospitalization, and at day 3 (study end).

- Satisfaction

Participants' satisfaction with the provided care by the nurses during daycare will be assessed using a 1-item self-created VAS scale ('not at all' to 'very much', 0-10 range). Satisfaction will be measured at day 3 (study end).

- General pain evaluation

Whether the pain following the operation has been better or worse than expected, will be measured using a 1-item self-created VAS scale (ranging from 'much worse than expected' to 'much better than expected', 0-10 range). Pain evaluation is measured at day 3 (study end).

- General evaluations regarding hospitalization

Patients' evaluations of their hospitalization are measured using two items i) How likely it is that the patient would recommend this hospital to other tonsillectomy patients (using an adapted item from the CQ Index[20] (0-10 scale 'would definitely not recommend' to 'would definitely recommend'); ii) Their overall rating of the quality of care provided by the hospital during hospitalization, using an adapted item from the CQ Index[20](0-10 scale, 'very poor care' to 'extremely good care'). This is measured at day 3 (study end).

15

Other outcomes

The following background characteristics of patients are measured pre-hospitalization;

- Socio-demographics

E.g. date of birth, gender, marital status, education, ethnicity, societal position, and date of operation.

- Functional health status

Measured using the COOP-WONCA; 7-item scale assessing several health status elements, e.g. physical fitness, on a 1-5 scale ranging from “not limited at all” to ‘severely limited’ [21 22].

- General experiences/expectations/attitudes medications

We will measure the extent to which patients generally i) benefit from, ii) have positive expectations towards the effect of, iii) have objections against taking medicines. This will be done using self-created VAS scales (ranging from ‘not at all’ to ‘very much’, 0-10 range).

- General reporting of pain

We will measure whether patients generally are inclined to report their pain using a self-created VAS scale (ranging from ‘never’ to ‘always’, 0-10 range)

- Attitudes towards operation

The extent to which participants i) are dreading, and ii) are afraid of the operation will be measured using two self-created VAS scales (ranging from ‘not at all’ to ‘very much’, 0-10 range).

In addition, we will measure:

- Data medical record

We will ask patients’ permissions to access the medical record. We will routinely use medical background data (diagnosis, weight, prescribed medication) and analgesic information (as aforementioned). If needed, additional data will be screened for (e.g. in cases of outlier data the medical record might provide useful information).

Background measures for nurses

The following nurses’ characteristics will be measured pre-hospitalization

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

16

- Socio-demographics

E.g. date of birth, gender, and type of nurse.

- Empathy personality trait:

We will measure nurses' empathic abilities using the Interactive Reactivity Index (IRI)[23]. The IRI consists of 28 items (e.g. "I often feel sorry for people who are less fortunate than me") which are scored on a 1-5 scale (ranging from 'describes me not at all' to 'describes me very well').

17

An overview of the measured outcomes at different time points is provided in Table 1.

Domain	Measure	Collected	Pre-hospitalization	Post-operation (at day care, day 1)	During hospitalization (pre-peri-operative, day 1)	Post-hospitalization (at home, day 2)	Post-hospitalization/study end (at home, day 3)
Pain perception/intensity	Standard hospital	Patient			x	x	x
Pain Expectations	Adapted VAS scale	Patient		x			
Overall benefit of analgesia	OBAS	Patient				x	x
Analgesic Dosage		medical record/patient			x	x	x
Analgesic Request		medical record			x		
Perceived empathy	CARE	Patient					x
Perceived expectation	Self-created VAS	Patient					x
Anxiety	State-anxiety (State)	Patient	X				x
Mood	PANAS	Patient	X				x

Protocol article Clinical study Spinoza V1.0 05-12-2016 clean version

18

Satisfaction	Self-created VAS scale	Patient					x
General pain evaluation	Self-created VAS Scale	Patient					x
General evaluation about hospitalization	Adapted CQ Index items	Patient					x
Socio demographics		Patient	X				
Functional health status	COOP-WONCA	Patient	X				
General Experiences/Expectations/Attitudes	Self-created VAS scales	Patient	X				
General reporting of pain	Self-created VAS scale	Patient	X				
Attitudes towards operation	Self-created VAS scale	Patient	X				
Data medical record	e.g. Diagnosis, weight, prescribed medication	Medical record	X		X		
Nurse – socio demographics		Nurse	X				
Nurse - empathy	IRI	Nurse	X				

Protocol article Clinical study Spinoza V1.0 05-12-2016 clean version

Table 1 – Overview measured outcomes at different time points

Adherence to the communication manipulation protocol:

To verify the fidelity of the communication manipulation, the interaction between nurses and patients will be audio-recorded. The adherence will be verified by listening back to a random sample (10% of the sample) of audio-recorded visits and to determine the adherence to the protocol (as is comparably done by[8]). Two research assistants who are not otherwise involved in the study will independently evaluate the audio-recordings on adherence to the protocol.

Data analysis plan

All data will be analysed using STATA 13.0 with two-sided significance testing at $p < .05$. All available data from patients will be included in the analysis and missing data might be imputed. An intention to treat (ITT) analysis will be performed, thereby also examining selective attrition.

Primary outcomes

Descriptive statistics will be calculated for patients' reported pain intensity (main outcome measure) for the different time points during and post- hospitalization. Since our design consists of a 2 (expectancy: enhanced vs. standard) by 2 (empathy: enhanced vs. standard) design all outcomes will be analysed using either analyses of variance (if focussed on a specific time point) or multilevel repeated measures regression analyses (if focused on different time points which means that several ratings are included for one person). Both communication elements (i.e. expectancy and empathy) are dummy coded. Main effects and interaction effects will be explored. New insights gathered during the analysing process might be examined (if feasible).

Secondary outcomes

Descriptive statistics will be calculated for secondary outcome measures. The effect of our manipulated variables will be analysed using analyses of variance.

Other outcomes

Frequencies and means will be calculated for the demographics. The four groups will be checked on equality by using chi-squared tests or analyses of variance (ANOVA). If groups differ on specific variables, these variables might be used as control variables in the multilevel analysis.

Adherence to communication protocol

Data of the audio-recordings are observed by trained coders on adherence to the protocol to verify fidelity. First, 10% of the audio-recordings are independently checked on adherence to the protocol. For this purpose, the main features of the four conditions are described and rated when listening to the audio-recordings. Second, inter-rater reliability between the coders of the outcomes will be assessed by calculating Cohen's kappa. Values ranging between 0.21 and 0.41 are considered fair, values between 0.41 and 0.60 moderate and values greater than 0.61 are considered good (i.e. substantial/almost perfect). We consider values as reliable if Cohen's kappa is greater than 0.41[24 25].

ETHICS AND DISSEMINATION

Risks and burden for participants

All participating patients receive usual care with regard to surgery, analgesia and pre- and post-operative treatment. There are no risks associated with this clinical study. The communication manipulation will be provided on top of standard care and is designed in such a way that there will be no harmful effects for patients. Although practitioners' communication is deliberately manipulated and associated with both positive and less positive effects, the communication manipulation does not cross important norms or values of acceptable behavior nor will it affect the psychological integrity of patients. Variations in nurse-patient interactions occur naturally within clinical settings, justifying our approach. Moreover, although patients are informed about the study by their treating clinicians, informed consent will be gathered by the research team. The clinical and research team will stress that participation is voluntary and will not affect standard clinical care. Patients are always free to withdraw their participation in the study. Last, it

21

can be a burden for patients to complete a few additional questionnaires. We attempt to decrease the burden by using short questionnaires. Results, ultimately, will provide more insight into the effect of communication on patient outcomes.

Adverse and serious adverse events

All adverse events reported spontaneously by the patient or observed by the clinical or research team will be recorded. All serious adverse events will be reported to the ethical committee who has approved the study and the online database. This will be done within 15 days (7 days for the first reporting if an SAE resulted in death or was life threatening). Due to the content of the intervention, we do not expect SAE's to happen. The research team, supported by the clinical team will regularly check the medical records for the occurrence of any adverse events and serious adverse events.

Confidentiality

Patients' data will be anonymized using an identification number. This code will be safeguarded by an independent contact person at NIVEL and this information will be kept on a protected drive using a protected file independently of the research data. The researchers involved in this study will have access to the research data. The audio-recordings will not be destroyed after the research, but will be added to the NIVEL audio/video database. At present, NIVEL has a database of around 18,000 (digitized) video-recorded and audio-recorded healthcare visits and a well-equipped infrastructure with computerized observation units.

Ethical approval

This study has received ethical approval from the ethical committee of the UMC Utrecht (number 16/144, NL55225.041) and the institutional review board of the participating hospital (number WO 16.506). All amendments will be notified to the ethical committee that gave a favorable opinion.

Trial registration

22

The study is registered at the Dutch Trial Register (Registration number NTR5994) which is the Primary Registry in the Netherlands.

Dissemination

At the minimum, the results of this study will be published in international peer-reviewed scientific journals. A lay summary of the results will be published as well and send to participants if they are interested.

DISCUSSION

This innovative study aims to manipulate communication to determine how expectations and empathy can lead to placebo-effects and help minimize patients' post-operative pain (among other outcomes). The results can help to shed more light on how communication can be used alongside medical care to enhance patients' outcomes for the better.

That being said, manipulating communication in clinical care poses methodological, ethical and logistical challenges. The success of the study will depend on the success of the manipulation. To ensure communication differs between the various groups, and to avoid contamination, all nurses have been trained and the research team is available (on and offsite) for questions, practice, and feedback. On most intervention days, a member of the research team is present at the daycare ward. This is much appreciated by nurses, and ensures that the appropriate manipulation is often practiced before a patient is admitted. Throughout an intervention day, the signposting of all systems (ward lists/hardcopy patient records) and the appropriate pocket cards with examples also serve as a constant reminder of the group allocation. The success of the manipulation is checked using the audio-recordings of nursing interactions. While varying communication, the ethical boundaries of not providing any suboptimal communication are and will be clearly adhered to and are stressed in contacts with involved health care professionals. Last, patients come in contact with many clinicians before and during hospitalization. Informing all clinicians and ensuring all but the daycare ward nurses will standardize their communication is crucial to ensure causal effects of the manipulated communication can be determined. Therefore, both the research and clinical team involved have ensured

23

many contact moments with clinicians to personally inform them about the study and appropriate information material has been circulated at study start.

Despite these challenges, we believe this study is of utmost importance to bring the field of communication and pain research forward. Without conducting controlled studies into the effect of communication, communication will always remain a soft-sided add-on. We hope this study and detailed protocol will provide an impetus for further work in this important area turning communication from 'art to science'.

Authors' contributions

JB is the Chief Investigator.

JB developed the initial concept of the study, supported by SvD and LV

LV, JB, SvD, and SI led on the protocol development, while all authors provided input for the trial design and protocol.

MG, BT, and GvD led on the standardization of hospital routine, pain protocol and medical content.

LV and SI (as of August 2016 also supported by MK) lead on the daily management of the trial, supported by MG, BT, GvD, SvD and JB

All authors have read, contributed and approved the final manuscript.

Acknowledgements

We thank Peter Spreeuwenberg for his help with the data analysis plan and power calculation. We thank the clinicians from the daycare ward, recovery and operation room, ENT and Anesthesia department for their help in facilitating the study logistics.

Funding

The study is funded by the Spinoza Prize from the Dutch Research Council awarded to Prof. dr. Jozien M. Bensing.

24

The funder had no role in the study design and decision to submit the report for publication. The funder will have no role in the collection, management, analysis and interpretation of data or writing and publication of future publications.

Competing interest

None declared

Legends

Figure 1. Study design.

Reference list

1. Miller FG, Kaptchuk TJ. The power of context: reconceptualizing the placebo effect. *J R Soc Med* 2008;101:222-25.
2. Finniss DG, Kaptchuk TJ, Miller F, et al. Biological, clinical, and ethical advances of placebo effects. *Lancet* 2010;375:686-95.
3. Turner JA, Deyo RA, Loeser JD, et al. The importance of placebo effects in pain treatment and research. *JAMA* 1994;271:1609-14.
4. Tracey I. Getting the pain you expect: mechanisms of placebo, nocebo and reappraisal effects in humans. *Nat Med* 2010;16:1277-83.
5. Mistiaen P, van Osch M, van Vliet L, et al. The effect of patient-practitioner communication on pain: a systematic review. *Eur J Pain* 2016;5:675-688.
6. Benedetti F, Maggi G, Lopiano L, et al. Open versus hidden medical treatments: The patient's knowledge about a therapy affects the therapy outcome. *Prevention & Treatment* 2003;6:1a.
7. Jubb J, Bensing JM. The sweetest pill to swallow: How patient neurobiology can be harnessed to maximise placebo effects. *Neurosci Biobehav Rev* 2013;37:2709-20.
8. Kaptchuk TJ, Kelley JM, Conboy LA, et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. *BMJ* 2008;336:999-1003.
9. Bensing JM, Verheul W. The silent healer: the role of communication in placebo effects. *Patient Educ Couns* 2010;80:293-99.
10. Verheul W, Sanders A, Bensing J. The effects of physicians' affect-oriented communication style and raising expectations on analogue patients' anxiety, affect and expectancies. *Patient Educ Couns* 2010;80:300-06
11. Manias E, Botti M, Bucknall T. Observation of pain assessment and management – the complexities of clinical practice. *J Clin Nurs* 2002;11(6):724-33
12. Breivik H, Borchgrevink P, Allen S, et al. Assessment of pain. *Br J Anaesth* 2008;101:17-24

25

13. Nederlandse Vereniging voor Anesthesiologie [Dutch Association for Anaesthesiology].. Richtlijn Postoperatieve pijn [Guideline for postoperative pain]. Utrecht, the Netherlands: 2012
14. Petersen GL, Finnerup NB, Groesen K, et al. Expectations and positive emotional feelings accompany reductions in ongoing and evoked neuropathic pain following placebo interventions. *Pain* 2014;155:2687-98.
15. Devilly GJ, Borkovec TD. Psychometric properties of the credibility/expectancy questionnaire. *J Behav Ther Exp Psychiatry* 2000;31:73-86.
16. Lehmann N, Joshi G, Dirkmann D, et al. Development and longitudinal validation of the overall benefit of analgesia score: a simple multi-dimensional quality assessment instrument. *Br J Anaesth* 2010;105:511-18
17. Mercer SW, Maxwell M, Heaney D, et al. The consultation and relational empathy (CARE) measure: development and preliminary validation and reliability of an empathy-based consultation process measure. *Fam Pract* 2004;21:699-705
18. Spielberger CD, Gorsuch RL, Lushene R, et al. State-trait anxiety inventory for adults: sampler set: manual, test, scoring key. Palo Alto, CA: Mind Garden Consulting Psychologists Press 1983.
19. Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. *J Pers Soc Psychol* 1988;54:1063-70.
20. van Kessel P, Hendriks M, van der Hoek L, et al. CQ Index Chronisch Hartfalen. Ontwikkeling van de vragenlijst en de ervaringen van mensen met chronisch hartfalen met de ziekenhuiszorg. [CQ Index Chronic heart failure. Development of the questionnaire and the experiences of chronic heart failure patients with hospital care]. Utrecht, the Netherlands: NIVEL 2015.
21. Van Weel C. Functional status in primary care: COOP/WONCA charts. *Disabil Rehabil* 1993;15:96-101
22. Van Weel C, Konig-Zahn C, Touw-Otten F, et al. Measuring functional status with the COOP/WONCA Charts. A manual. Groningen, the Netherlands: Noordelijk Centrum voor Gezondheidsvraagstukken (NCG)/Northern Centre of Health Care Research (NCH) 2012
23. Davis MH. Measuring individual differences in empathy: evidence for a multidimensional approach. *J Pers Soc Psychol* 1983;44::113-126.
24. Sim J, Wright CC. The kappa statistic in reliability studies: use, interpretation, and sample size requirements. *Phys Ther* 2005;85::257-68.
25. Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics* 1977:159-74.

Figure 1. Study design.

		Expectancy	
		enhanced	standard
Empathy	enhanced	Group 1	Group 2
	standard	Group 3	Group 4

For peer review only



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	__1__
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	__3__
	2b	All items from the World Health Organization Trial Registration Data Set	__NA-registered at the Dutch Trial Register__
Protocol version	3	Date and version identifier	__NA, Not in article, we currently use protocol V4.0 16-08-2016__
Funding	4	Sources and types of financial, material, and other support	__23__
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	__1-2__
	5b	Name and contact information for the trial sponsor	__23__
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	__23__

1
2
3 5d Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint
4 adjudication committee, data management team, and other individuals or groups overseeing the trial, if
5 applicable (see Item 21a for data monitoring committee) _____NA, a
6 collaboration
7 agreement
8 between the
9 hospital (OLVG)
10 and NIVEL has
11 been
12 created_____

13 **Introduction**

14
15 Background and 6a Description of research question and justification for undertaking the trial, including summary of relevant
16 rationale studies (published and unpublished) examining benefits and harms for each intervention ___4-6_____
17
18 6b Explanation for choice of comparators ___4-6_____
19
20 Objectives 7 Specific objectives or hypotheses ___5-6_____
21
22 Trial design 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group),
23 allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) ___6_____
24
25

26 **Methods: Participants, interventions, and outcomes**

27
28 Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will
29 be collected. Reference to where list of study sites can be obtained ___6_____
30
31 Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and
32 individuals who will perform the interventions (eg, surgeons, psychotherapists) ___6-7_____
33
34 Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when they will be
35 administered ___9-11_____
36
37 11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose
38 change in response to harms, participant request, or improving/worsening disease) ___12,7_____
39
40 11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence
41 (eg, drug tablet return, laboratory tests) ___9,11,19,20_____
42
43
44
45

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	_20,6,_____
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	_12-20_____
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	_8,9,11,12-19___
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	_7_____
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	_8_____

Methods: Assignment of interventions (for controlled trials)

Allocation:

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	_8_____
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	_8_____
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	_8_____
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	_11, 9_____
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	_12_____

Methods: Data collection, management, and analysis

5	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	_11-19_____
6	methods			
11		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	_21,7_____
14	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	_21_____
18	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	_19_____
22		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	_20_____
24		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	_19_____
27	Methods: Monitoring			
29	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	_NA, no DMC has been set up_____
35		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	_NA, no interim analyses are performed_____
39	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	_21_____

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Auditing 23 Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor __NA__

Ethics and dissemination

Research ethics approval 24 Plans for seeking research ethics committee/institutional review board (REC/IRB) approval __21__

Protocol amendments 25 Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators) __21__

Consent or assent 26a Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32) __8,12__

26b Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable __NA__

Confidentiality 27 How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial __21__

Declaration of interests 28 Financial and other competing interests for principal investigators for the overall trial and each study site __24__

Access to data 29 Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators __21__

Ancillary and post-trial care 30 Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation __12__

Dissemination policy 31a Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions __22__

31b Authorship eligibility guidelines and any intended use of professional writers __NA – ICMJE criteria will be used__

1
2
3 31c Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code NA
4

5 **Appendices**
6

7 Informed consent 32 Model consent form and other related documentation given to participants and authorised surrogates Not provided in
8 materials article
9

10 Biological 33 Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular NA
11 specimens analysis in the current trial and for future use in ancillary studies, if applicable
12

13 *It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.
14 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons
15 "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

BMJ Open

Examining the effects of enhanced provider-patient communication on post-operative tonsillectomy pain; Protocol of a Randomized Controlled Trial performed by nurses in daily clinical care.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-015505.R1
Article Type:	Protocol
Date Submitted by the Author:	29-Aug-2017
Complete List of Authors:	van Vliet, Liesbeth; Nederlands Instituut voor Onderzoek van de Gezondheidszorg van Dulmen, Sandra; NIVEL; Radboud University Medical Center , Department of Primary and Community Care Thiel , B; Onze Lieve Vrouwe Gasthuis, Department of Anaesthesiology van Deelen, G; Onze Lieve Vrouwe Gasthuis, Department of ENT Immerzeel, S; Nederlands Instituut voor Onderzoek van de Gezondheidszorg, Communication Godfried, M; Onze Lieve Vrouwe Gasthuis, Department of Anesthesiology Bensing, Jozen; NIVEL, Netherlands Institute for Health Services Res
Primary Subject Heading:	Communication
Secondary Subject Heading:	Anaesthesia
Keywords:	communication, placebo-effects, Pain management < ANAESTHETICS, tonsillectomy, randomized controlled trial

SCHOLARONE™
Manuscripts

1

Title page

Title: Examining the effects of enhanced provider-patient communication on post-operative tonsillectomy pain; Protocol of a Randomized Controlled Trial performed by nurses in daily clinical care.

Van Vliet, van Dulmen, Thiel, van Deelen, Immerzeel, Godfried, Bensing

Corresponding author:

Dr Liesbeth M van Vliet

NIVEL (Netherlands institute for health services research), Department of Communication

P.O.Box 1568

3500 BN Utrecht

The Netherlands

Email: l.vanvliet@nivel.nl

Telephone number: 0031 30 27 29 632

Prof. dr. Sandra van Dulmen

1. NIVEL, Department of Communication

Utrecht, the Netherlands

Email: S.vandulmen@nivel.nl

2. Department of Primary and Community Care, Radboud University Medical Center,

Nijmegen, the Netherlands

3. Science Centre Health and Technology, Faculty of Health Sciences, University College of Southeast Norway, Drammen, Norway

Bram Thiel MSc

OLVG Hospital , Department of Anesthesiology

Amsterdam, the Netherlands

Email: B.Thiel@olvg.nl

Dr G. W. van Deelen

Protocol article Clinical study Spinoza Revised Manuscript Clean Copy V1.0 25082017

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

2

OLVG Hospital, Department of ENT
Amsterdam, the Netherlands
Email: G.W.vanDeelen@olvg.nl

Stephanie Immerzeel MSc
NIVEL, Department of Communication
Utrecht, the Netherlands
Email: S.Immerzeel@nivel.nl

Dr Marc B Godfried
OLVG Hospital, Department of Anesthesiology
Amsterdam, the Netherlands
Email: M.B.Godfried@olvg.nl

Prof. dr. Jozien M Bensing
NIVEL, Department of Communication
Utrecht, the Netherlands
Email: j.bensing@nivel.nl

Word count: 5317

Number of Figures: 1

Number of Tables: 1

Number of References: 28

Key words: Communication, placebo-effects, pain management, tonsillectomy,
randomized controlled trial

3

Abstract

Introduction: Placebo effects (true biopsychological effects not attributable to the active ingredients of medical technical interventions) can be attributed to several mechanisms, such as expectancy manipulation and empathy manipulation elicited by a provider's communication. So far, effects have primarily been shown in laboratory settings. The aim of this study is to determine the separate and combined effects of expectancy manipulation and empathy manipulation during pre- and post-operative tonsillectomy analgesia care on clinical adult patients' outcomes.

Methods and analysis: Using a two by two randomized controlled trial 128 adult tonsillectomy patients will be randomly assigned to one out of four conditions differing in the level of expectancy manipulation (standard versus enhanced) and empathy manipulation (standard versus enhanced). Daycare ward nurses are trained to deliver the intervention, while patients are treated via the standard analgesia protocol and hospital routines. The primary outcome, perceived pain, is measured via hospital routine by a Numeric Rating Scale, and additional pre-, peri- and post-hospitalization questionnaires are completed (until day 3, i.e. 2 days after the operation). The manipulation is checked using audio-recordings of nurse-patient interactions.

Ethics and dissemination: Although communication is manipulated, the manipulations do not cross norms or values of acceptable behavior. Standard medical care is provided. The ethical committee of the UMC Utrecht and the local OLVG hospital committee approved the study. Results will be published via (inter)national peer-reviewed journals and a lay publication.

Registration details: NTR5994 (Dutch Trial Register)

Strengths:

- This study is a RCT on the (placebo) effects of communication on top of standard medical care, building the evidence-base of communication.

Limitations:

- The success of the intervention will depend on the ability of nurses to carry out the different communication styles successfully.

INTRODUCTION

In clinical care, patients' outcomes are not only influenced by the active ingredients of drugs or other medical technical interventions, but also by the context in which care is delivered. Such biopsychosocial effects on patients' outcomes that are not attributable to the active ingredients of treatments or interventions are called 'non-specific' or 'placebo-effects'[1 2]. They are real and robust, occurring on top of natural history and regression to the mean[3], and can be observed alongside 'sham-treatments' as well as 'real treatments'[4].

Several mechanisms underlie the generation of placebo-effects on patient outcomes such as pain[5]. A well-understood mechanism is the manipulation of expectations. According to a recent systematic review of our research group, manipulating patients' expectations seems capable of influencing clinical patients' pain perceptions[6]. For example, the verbal suggestion that a drug is an active pain killer is more effective than receiving the same dosage medication without such a suggestion[7]. Manipulating expectations also contribute to the recent described positive effects of open-label placebos (inert treatments being described as such)[8]. A less-well understood mechanism is the communication of empathy in health care professional-patient encounters. Only few scholars have pointed out the potential role of the professional-patient relationship in explaining placebo-effects[9-11]. In our systematic review, we found that empathy had a less strong effect on pain compared to expectations[6]; but studies used different empathy operationalization and empathy was often manipulated together with other elements of the clinical encounter, making it difficult to draw strong conclusions from empathy[6].

When looking at these mechanisms, it seems reasonable that health care professionals' communication can influence them, and can thus produce placebo-effects. Until recently, however, the entities of communication and placebo-effects have hardly been integrated[11]. Communication is traditionally associated with 'art, not science' and placebos with 'evidence-based medicine' in which their effects are typically ruled out by the study design of randomized controlled trials (RCTs).

5

The tide is changing. A landmark-study led by Kaptchuk et al 2008[10] found that placebo-acupuncture delivered with high outcome expectations and an empathic approach led to statistically and clinically significant improvements in the functioning of patients with irritable bowel syndrome compared to placebo-acupuncture delivered without expectations and empathy. The distinct and combined effects of both mechanism, and the effects alongside an active treatment remain, however, unknown from this study.

Our research group has started to unravel the potential separate and combined effects of both expectancy manipulation and empathy manipulation in highly controlled settings. Using scripted video-vignettes and role-play studies, we found that expectancy mainly influences cognitive outcomes (e.g. expected treatment effect) and empathy mainly affective outcomes (e.g. anxiety). The largest positive effects were found when the two elements were combined and a physician raised high expectations meanwhile communicating in a warm, empathic manner[12 13]. However, whether these distinct and combined effects also translate to the clinical setting, alongside an active intervention remains, as yet, an unanswered question. Answering this question is important, as it will provide insight into how specific communication elements can influence specific health outcomes.

Study objective

This study therefore aims to disentangle the role of communication in eliciting placebo-effects in the clinical setting within the context of standard medical care. More specifically, the objective is to determine the separate and combined effects of expectancy manipulation (standard versus enhanced) and empathy manipulation (standard versus enhanced) during pre- and post-operative tonsillectomy analgesia care on clinical adult patients' outcomes (main outcome measure is pain perception). This will be studied using a 2 by 2 RCT design. By following this approach the evidence base on the effects of expressed outcome expectancy and conveyed empathy will be built in clinical care.

Accompanying the study objective, the goals of this study are in subsequent order:

6

1. To examine whether adult patients following tonsillectomy in the enhanced outcome expectancy condition will experience less pain (and other outcomes), compared to patients in the standard condition.
2. To examine whether adult patients following tonsillectomy in the enhanced empathy communication condition will experience less pain (and other outcomes) compared to patients in the standard empathy communication condition.
3. To examine the interaction effects of the different levels of outcome expectancy and empathy on adult patients' experiences of pain (and other outcomes).

METHODS AND ANALYSIS

Design and setting

A four-arm (2 by 2 design) single-blind randomized controlled trial will be conducted at the daycare nursing wards on two locations of a Dutch general hospital (OLVG Amsterdam), in which adult tonsillectomy patients are pre- and postoperatively monitored and treated by nurses. Patients will be randomly assigned to one out of 4 arms, which vary in the induction of expectations (standard vs enhanced), and (the level of) nurses' communication of empathy (standard vs enhanced). Depending on the patient's allocation, nurses will express a standard or enhanced outcome expectation of patients' pain, and provide care in a standard or enhanced empathic manner. See figure 1 for the study design. All patients will be treated according to the usual analgesic treatment protocol and daily routine care of the hospital. Recruitment started in August 2016 and will presumably continue until early 2018.

Patients

This study focuses on adult tonsillectomy patients. This population was carefully selected as it is a homogeneous population. These patients are young adults, generally aged 18-35, without complex comorbidity (ASA 1) and lack a history of chronic pain. Moreover, tonsillectomy is generally accepted as a strong confound nociceptive trigger resulting into high levels of postoperative pain that only lasts for a relatively short period of time (1-2 weeks).

7

Inclusion criteria

In order to be eligible to participate in this study, a patient must meet the following criteria:

- Scheduled for tonsillectomy in daycare
- ≥ 18 years of age
- Speaking and understanding of the Dutch language
- Having mental capacity

Exclusion criteria

A potential patient who meets the following criteria will be excluded from participation in this study:

At study start (during inclusion process):

- Not scheduled for tonsillectomy in day care
- < 18 years of age
- Not speaking and understanding of the Dutch language
- Lacking mental capacity (cognitive decline, dementia)

During the course of the study:

- Patients who experience a post-operative bleeding will be excluded.
- The health care professionals involved and research team can decide to withdraw a patient from the study for urgent medical reasons (e.g. if patients are not discharged on the day of operation due to complications).

If a patient drops-out, data until exclusion will be included in the analyses unless the patient objects to this (this will be asked upon exclusion).

Sample size

The sample size calculation is based on the primary outcome, i.e. pain. This calculation is based on a previous similar study[7], in which an open versus hidden administration of analgesic showed a difference of 1.2 and a total variance of 2.18. Based on a power of .80

8

and alpha of .05, and including an interaction-effect (with a within variance of 1.92), this results in a needed sample size of 32 patients per arm and $4 \times 32 = 128$ patients in total.

Recruitment

The recruitment of patients occurs in several steps:

- i) Patients are approached for the study while discussing the operation with their consulting ear nose and throat specialist (i.e. ENT doctor). All eligible and interested patients are provided with a Patient Information Folder (PIF) and informed consent form. The PIF omits specific study aims, but mentions that communication will be manipulated. It is stressed that participation is free of choice and will not affect usual medical care.
- ii) During the pre-operative examination, which is mostly conducted within a few days of the ENT consultation, the anaesthesiology clinician asks whether the patient is informed about the study. If not, they will provide them the PIF and consent form. They will ask whether the patient is interested in participation and whether the research team can call the patient to provide them with more information. This response is noted in the electronic record and transferred to the researchers via an (automated) email.
- iii) The research team will call the patient, explain the study in more detail and ask the patient to return the completed informed consent form.

Patients who are already planned for surgery when the study opens (the normal time between ENT consultation and the operation is 6-8 weeks) will be called by involved health care practitioners (from the ENT/Anaesthesiology department). They are informed about the study via telephone. In case they are interested, their name and telephone number are transferred to the researchers. The researchers will call the patient, and send them an information letter and consent form which participants can complete and return in case they are willing to participate.

Randomization

Upon providing informed consent patients are randomized using a random number generator (1:1:1:1: allocation rate). Assignments will be provided via sequentially

9

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

numbered opaque sealed envelopes. A secretary not otherwise involved in the study will open the assignment envelopes.

After patients are randomized, the research team will inform the health care professionals about their inclusion. They will insert this information in the medical records of the hospital system (EPIC). Moreover, they will inform the day care administrators and key contact persons about the patients that are scheduled in the upcoming week or days and which condition they are randomized to. On the day of admission, the researchers will ensure that all appropriate systems (e.g. the ward lists and the hard copy patient records) are adequately signposted with the patients' condition. We will use color codes for this to avoid unblinding patients. Only one patient per room is included at any time point.

Intervention

The intervention consists of a (protocolled) communication manipulation on top of standard analgesic treatment. Nurses at the day care ward will incorporate an (protocolled) expectancy manipulation (standard versus enhanced) related to the effects of the pain medication and empathy manipulation (standard versus enhanced) into their communication. The communication intervention will be provided at all nurse-patient communication moments during patients' stay at the day care ward (pre- and post-operation, day 1, the daycare wards are open between 7AM-6PM and 6.45AM-7PM respectively), and during the nurses' telephone consultation with patients the day post-discharge (day 2). In practice, this means that all communication patients receive from daycare ward nurses during this time frame will be according to patients' assigned condition. This includes interactions during intake, pain assessments, medication allocation, and transferal to the operation theater and from the post anesthesia care unit (PACU), discharge, and all other interactions due to patients' questions or medical need.

All nurses will receive training to ensure their ability to perform the different communication manipulations. We will make use of a professional trainer and comprehensive training protocol including scripts (i.e. written examples), video-examples, and role-play. Moreover, posters are placed in the communal spaces for nurses with

10

1
2
3 information about the study; e.g. examples of the manipulations and study procedures.
4
5 Pocket cards with examples of the manipulations are provided. To ensure the
6
7 communication differs between the 4 conditions and to minimize carry-over effects (e.g.
8
9 nurses' stressing enhanced expectations display automatically an enhanced empathy
10
11 style), the 4 conditions are trained separately and the posters and pockets cards focus on
12
13 the 4 different conditions. The importance of the manipulations being successful in order
14
15 to draw conclusions from the found results is stressed during the training day.
16

17 18 *Expectancy manipulation*

19
20 In the standard condition nurses do not aim to create the expectation that the pain
21
22 medication will work very well. They might use sentences such as "The medications
23
24 attempt to reduce your pain ever so slightly", or "This is your pain medication".
25

26
27 In the enhanced condition nurses aim to create the expectation that the pain medication
28
29 will work very well. They might use sentences such as: "The medications I am giving you
30
31 now will lead to a strong decrease of your pain", or "This pain medication is known for
32
33 working very well".
34

35 36 *Empathy manipulation*

37
38 In the standard condition nurses aim to create a neutral atmosphere which is standard.
39
40 They will be trained to (amongst other behavior) keep standing when communicating
41
42 with patients, react with standard empathy to patients' cues and concerns, not explore
43
44 concerns in detail, to not express extra interest in the patient as a person, to not pay extra
45
46 attention to not interrupting patients, and to not make extra eye contact.
47

48
49 In the enhanced condition, nurses aim to create an atmosphere, which is extra warm and
50
51 extra friendly. They will be trained to (amongst other behavior) introduce themselves
52
53 properly, sit while communicating with patients, react extra empathically to patients' cues
54
55 and concerns (verbal and nonverbal) and take their concerns seriously, to show extra
56
57 interest in the patient as a person, to not interrupt the patient, and to make adequate eye
58
59 contact.
60

11

1
2
3
4
5 It should be noted that the communication manipulation does not cross important norms
6 or values of acceptable behavior and that the psychological integrity of patients will not be
7 harmed. An observational study among clinical postsurgical patients showed that nurse-
8 patient interactions are often subject to interruptions related to other tasks e.g. searching
9 for equipment, answering telephone calls, or being interrupted by other
10 professionals[14]. The interruptions and nurses' attempts to address competing demands
11 impact on the time and attention spent with patients. It can therefore be assumed that
12 variations in communication are inherently due to clinical encounters. This was also
13 confirmed by field observations conducted by the research team before study start. The
14 aforementioned developed scripts/examples which are used in the training have been
15 commented upon by nurses and researchers in a pilot study to ensure they are realistic
16 and do not trespass ethical boundaries and have been finalized in collaboration with
17 involved clinicians.

30 *Standardizing of communication*

31
32 The communication patients receive from other clinicians involved during their
33 hospitalization (e.g. from the surgical team working in the operation theater and the
34 clinical team working in the PACU) will be standardized as much as possible. Also the
35 communication during the pre-operative ENT and Anaesthesiology visit will be
36 standardized as much as possible. Involved health care professionals will be informed of
37 the study aims and the importance to keep their communication neutral (if possible) (i.e.
38 to not provide extra empathy or raise extra expectations about pain) for included patients.
39 This is feasible, as the ENT and anesthesiology team are involved in the study, and it is
40 uncommon for patients to ask about pain medication during their time at the PACU.

50 *Blinding*

51 Patients will be blinded to the specific study aims and treatment allocation.
52
53 The involved health care personnel cannot be blinded. All health care personnel involved
54 will receive clear and specific instructions about informing and including patients to
55 preserve experimental control. Besides, all interactions within the study between nurses
56
57
58
59

12

and patients will be audio-recorded to evaluate the fidelity of the communication manipulation.

Study procedure

After receiving informed consent, the research team will send a baseline questionnaire to the patient. Completion of this questionnaire will be done at home and will take no more than 20 minutes. Post-operatively (at daycare, day 1) a short (5-minute) questionnaire is administered. As part of routine care, pre- and post- operatively, patients rate their level of pain. At day 2 (the day after discharge) patients will complete another questionnaire about their pain and medication use. At day 3 a last questionnaire will be completed which will take 20 minutes. Patients are given the choice between paper and pencil and online completion of questionnaires. This timeframe of follow-up is chosen as we expect the effect of the intervention (delivered within a few hours by daycare ward nurses solely) to wane within a few days.

Moreover, the interactions between involved nurses and included patients will be recorded. Nurses will be provided with a portable audio-recording device with microphone. During every visit, the nurses will mention patient's identification number by means of reference, to protect patients' privacy. At day 4 (3 days after discharge) patients will receive a debriefing letter by postal mail which will inform them about the study aims and their assigned condition. If they wish to receive more information they can contact the research team.

Withdrawal of individual patients

Patients can leave the study at any time for any reason if they wish to do so without any consequences. The health care professionals involved and research team can decide to withdraw a patient from the study for urgent medical reasons (e.g. a bleeding after operation). If a patient drops-out, the research team is informed of this. Patients will continue to receive standard medical care and communication.

Informed consent nurses

13

1
2
3 Nurses involved in the study will be asked to participate as participants using an
4 information sheet and a consent form. They will be asked to complete the consent form
5 and a questionnaire about their background characteristics. We will offer them, at study
6 end, participation in a (accredited) communication training to thank them for their
7 participation in this project.
8
9
10
11
12

13 Outcomes

14 *Main study outcome:*

- 15 • Pain perception/intensity

16 As part of routine care, during hospitalization and post-hospitalization patients' pain will
17 be assessed on the basis of a Numeric Rating Scale (NRS) (0-10), ranging from 'no pain' to
18 'worst imaginable pain' [15 16]. Pain is rated preoperatively at daycare ward, at the PACU
19 , and postoperatively at daycare ward. On study day 2, one day after discharge, daycare
20 ward nurses will contact the patients by telephone and again assess their pain. On top of
21 this standard routine, pain is assessed at home on day 2 and day 3 (study end).
22
23
24
25
26
27
28
29
30
31

32 *Secondary study outcome*

33 In the patient questionnaires, the following secondary outcomes will be assessed:

- 34 • Pain expectations

35 Patients' pain expectations are measured using two items (both measured using a self-
36 created Visual Analogue Scale (VAS); i) Patients' pain expectations for the few days
37 following the operation (VAS ranging from 'no pain' to 'the most intense pain imaginable',
38 ranging from 0-10, adapted from Petersen et al., 2014[17]); ii) Patients' expectations of
39 improvement in pain following receiving pain medication (VAS ranging from '0%
40 improvement' (no improvement) to '100% improvement' (most improvement
41 imaginable), adapted from the Credibility and Expectancy Questionnaire (CEQ)[18]. These
42 questions will be assessed post-operatively (during hospitalization).
43
44
45
46
47
48
49
50
51

- 52 • Overall benefit of analgesia

53 The overall benefit of analgesia score (OBAS) will be assessed[19]. The OBAS is a
54 multidimensional 7-item instrument in which patients indicate (on a 0-4 scale, ranging
55 from 'not at all' to 'very much') the level of current pain and distress arising from several
56
57
58
59
60

14

1
2
3 symptoms such as itch. The OBAS is measured post-hospitalization (at home) at day 2 and
4
5 3 (study end).
6

- 7 • Analgesic dosage

8
9 The total dosage of administered analgesics will be assessed during hospital stay and
10 noted in the medical record. The total dosage of administered analgesic at home post-
11 operation will be assessed at day 2 and 3 (study end) by asking patients to indicate which
12 pain medication they use/have used.
13

- 14 • Analgesic request by a patient

15
16 Analgesic request will be assessed during hospital stay and noted in the medical record.
17

- 18 • Perceived empathy

19
20 Perceived empathy will be determined using the Consultation and Relational Empathy
21 Measure (CARE)[20] in which the term 'doctor' is replaced with 'nurse' and 'consultation'
22 is replaced with 'contact' (10 items, 1-5 scale ranging from 'poor' to 'excellent' (and 'not
23 relevant'), e.g. "How was the nurse at showing care and compassion"). Perceived empathy
24 is measured at day 3 (study end).
25

- 26 • Perceived expectation

27
28 We will measure the extent to which participants thought nurses had induced the
29 expectation that medication would be effective to decrease their pain. This will be
30 assessed using a 1-item self-created VAS scale ('no effect at all' to 'a lot of effect', ranging
31 from 0-10). Perceived expectation will be measured at day 3 (study end).
32

- 33 • State anxiety

34
35 Patients' level of anxiety will be measured by the Dutch 10-item State measure of the
36 State-Trait Anxiety Inventory (STAI-State)[21](1-4 scale ranging 'not at all' to 'very
37 much'). Patients' anxiety is assessed pre-hospitalization, and at day 3 (study end).
38

- 39 • Mood

40
41 Mood will be measured using the Positive and Negative Affect Schedule (PANAS)[22] (20-
42 items, 1-5 scale ranging from 'not at all' to 'very much' e.g. "I am excited" or "I am upset").
43 Mood is measured pre-hospitalization, and at day 3 (study end).
44

- 45 • Satisfaction

15

Participants' satisfaction with the provided care by the nurses during daycare will be assessed using a 1-item self-created VAS scale ('not at all' to 'very much', 0-10 range). Satisfaction will be measured at day 3 (study end).

- General pain evaluation

Whether the pain following the operation has been better or worse than expected, will be measured using a 1-item self-created VAS scale (ranging from 'much worse than expected' to 'much better than expected', 0-10 range). Pain evaluation is measured at day 3 (study end).

- General evaluations regarding hospitalization

Patients' evaluations of their hospitalization are measured using two items i) How likely it is that the patient would recommend this hospital to other tonsillectomy patients (using an adapted item from the CQ Index[23] (0-10 scale 'would definitely not recommend' to 'would definitely recommend'); ii) Their overall rating of the quality of care provided by the hospital during hospitalization, using an adapted item from the CQ Index[23](0-10 scale, 'very poor care' to 'extremely good care'). This is measured at day 3 (study end).

Other outcomes

The following background characteristics of patients are measured pre-hospitalization;

- Socio-demographics

E.g. date of birth, gender, marital status, education, ethnicity, societal position, and date of operation.

- Functional health status

Measured using the COOP-WONCA; 7-item scale assessing several health status elements, e.g. physical fitness, on a 1-5 scale ranging from "not limited at all" to 'severely limited'[24 25].

- General experiences/expectations/attitudes medications

We will measure the extent to which patients generally i) benefit from, ii) have positive expectations towards the effect of, iii) have objections against taking medicines. This will be done using self-created VAS scales (ranging from 'not at all' to 'very much', 0-10 range).

- General reporting of pain

16

We will measure whether patients generally are inclined to report their pain using a self-created VAS scale (ranging from 'never' to 'always', 0-10 range)

- Attitudes towards operation

The extent to which participants i) are dreading, and ii) are afraid of the operation will be measured using two self-created VAS scales (ranging from 'not at all' to 'very much', 0-10 range).

In addition, we will measure:

- Data medical record

We will ask patients' permissions to access the medical record. We will routinely use medical background data (diagnosis, weight, prescribed medication) and analgesic information (as aforementioned). If needed, additional data will be screened for (e.g. in cases of outlier data the medical record might provide useful information).

Background measures for nurses

The following nurses' characteristics will be measured at study start.

- Socio-demographics

E.g. date of birth, gender, and type of nurse (i.e. nurse in training, regular nurse, specialized nurse).

- Empathy personality trait:

We will measure nurses' empathic abilities using the Interactive Reactivity Index (IRI)[26]. The IRI consists of 28 items (e.g. "I often feel sorry for people who are less fortunate than me") which are scored on a 1-5 scale (ranging from 'describes me not at all' to 'describes me very well').

An overview of the measured outcomes at different time points is provided in Table 1.

Domain	Measure	Collected	Pre-hospitalization	Post-operation (at day care, day 1)	During hospitalization (pre-peri-post operative, day 1)	Post-hospitalization (at home, day 2)	Post-hospitalization/study end (at home, day 3)
Pain perception/intensity	Standard hospital NRS	Patient			x	x	x
Pain Expectations	Adapted VAS scale	Patient		x			
Overall benefit of analgesia	OBAS	Patient				x	x
Analgesic Dosage		medical record/patient			x	x	x
Analgesic Request		medical record			x		
Perceived empathy	CARE	Patient					x
Perceived expectation	Self-created VAS	Patient					x
Anxiety	State-anxiety (State)	Patient	X				x
Mood	PANAS	Patient	X				x

Protocol article Clinical study Spinoza Revised Manuscript Clean Copy V1.0 25082017

18

Satisfaction	Self-created VAS scale	Patient					x
General pain evaluation	Self-created VAS Scale	Patient					x
General evaluation about hospitalization	Adapted CQ Index items	Patient					x
Socio demographics		Patient	X				
Functional health status	COOP-WONCA	Patient	X				
General Experiences/Expectations/Attitudes	Self-created VAS scales	Patient	X				
General reporting of pain	Self-created VAS scale	Patient	X				
Attitudes towards operation	Self-created VAS scale	Patient	X				
Data medical record	e.g. Diagnosis, weight, prescribed medication	Medical record	X		X		
Nurse – socio demographics		Nurse	At study start				
Nurse - empathy	IRI	Nurse	At study start				

Protocol article Clinical study Spinoza Revised Manuscript Clean Copy V1.0 25082017

1
2
3
4
5 Table 1 – Overview measured outcomes at different time points
6
7
8

9 *Adherence to the communication manipulation protocol:*

10 To verify the fidelity of the communication manipulation, the interaction between nurses
11 and patients will be audio-recorded. The adherence will be verified by listening back to a
12 random sample (10% of the sample) of audio-recorded visits and to determine the
13 adherence to the protocol (as is comparably done by[10]). Two research assistants who
14 are not otherwise involved in the study will independently evaluate the audio-recordings
15 on adherence to the protocol.
16
17
18
19
20
21

22
23 **Data analysis plan**

24 All data will be analysed using STATA 13.0 with two-sided significance testing at $p < .05$.
25 All available data from patients will be included in the analysis and missing data might be
26 imputed. An intention to treat (ITT) analysis will be performed, thereby also examining
27 selective attrition.
28
29
30
31
32
33

34 *Primary outcomes*

35 Descriptive statistics will be calculated for patients' reported pain intensity (main
36 outcome measure) for the different time points during and post- hospitalization. Since our
37 design consists of a 2 (expectancy: enhanced vs. standard) by 2 (empathy: enhanced vs.
38 standard) design all outcomes will be analysed using either analyses of variance (if
39 focussed on a specific time point) or multilevel repeated measures regression analyses (if
40 focused on different time points which means that several ratings are included for one
41 person). Both communication elements (i.e. expectancy and empathy) are dummy coded.
42 Main effects and interaction effects of expectancy and empathy will be explored. New
43 insights gathered during the analysing process might be examined (if feasible).
44
45
46
47
48
49
50
51
52

53 *Secondary outcomes*

54 Descriptive statistics will be calculated for secondary outcome measures. The effect of our
55 manipulated variables will be analysed using analyses of variance.
56
57
58
59
60

Other outcomes

Frequencies and means will be calculated for the demographics. The four groups will be checked on equality by using chi-squared tests or analyses of variance (ANOVA). If groups differ on specific variables, these variables might be used as control variables in the multilevel analysis.

Adherence to communication protocol

Data of the audio-recordings are observed by trained coders on adherence to the protocol to verify fidelity. First, 10% of the audio-recordings are independently checked on adherence to the protocol. For this purpose, the aforementioned main (verbal) features of the manipulations (see p10) are described and rated for their occurrence when listening to the audio-recordings. Using this it is determined to which of the 4 conditions the audio recording belongs to. Second, inter-rater reliability between the coders of the outcomes will be assessed by calculating Cohen's kappa. Values ranging between 0.21 and 0.41 are considered fair, values between 0.41 and 0.60 moderate and values greater than 0.61 are considered good (i.e. substantial/almost perfect). We consider values as reliable if Cohen's kappa is greater than 0.41[27 28].

ETHICS AND DISSEMINATION

Risks and burden for participants

All participating patients receive usual care with regard to surgery, analgesia and pre- and post-operative treatment. There are no risks associated with this clinical study. The communication manipulation will be provided on top of standard care and is designed in such a way that there will be no harmful effects for patients. Although practitioners' communication is deliberately manipulated and associated with both positive and less positive effects, the communication manipulation does not cross important norms or values of acceptable behavior nor will it affect the psychological integrity of patients. Variations in nurse-patient interactions occur naturally within clinical settings, justifying our approach. Moreover, although patients are informed about the study by their treating clinicians, informed consent will be gathered by the research team. The clinical and

21

1
2
3 research team will stress that participation is voluntary and will not affect standard
4 clinical care. Patients are always free to withdraw their participation in the study. Last, it
5 can be a burden for patients to complete a few additional questionnaires. We attempt to
6 decrease the burden by using short questionnaires and limiting follow-up to 3 days.
7 Results, ultimately, will provide more insight into the effect of communication on patient
8 outcomes.
9
10
11
12
13

14 15 16 **Adverse and serious adverse events**

17 All adverse events reported spontaneously by the patient or observed by the clinical or
18 research team will be recorded. All serious adverse events will be reported to the ethical
19 committee who has approved the study and the online database. This will be done within
20 15 days (7 days for the first reporting if an SAE resulted in death or was life threatening).
21 Due to the content of the intervention, we do not expect SAE's to happen. The research
22 team, supported by the clinical team will regularly check the medical records for the
23 occurrence of any adverse events and serious adverse events.
24
25
26
27
28
29
30
31

32 **Confidentiality**

33 Patients' data will be anonymized using an identification number. This code will be
34 safeguarded by an independent contact person at NIVEL and this information will be kept
35 on a protected drive using a protected file independently of the research data. The
36 researchers involved in this study will have access to the research data. The audio-
37 recordings will not be destroyed after the research, but will be added to the NIVEL
38 audio/video database. At present, NIVEL has a database of around 18,000 (digitized)
39 video-recorded and audio-recorded healthcare visits and a well-equipped infrastructure
40 with computerized observation units.
41
42
43
44
45
46
47
48
49

50 **Ethical approval**

51 This study has received ethical approval from the ethical committee of the UMC Utrecht
52 (number 16/144, NL55225.041) and the institutional review board of the participating
53 hospital (number WO 16.506). All amendments will be notified to the ethical committee
54 that gave a favorable opinion.
55
56
57
58
59

22

Trial registration

The study is registered at the Dutch Trial Register (Registration number NTR5994) which is the Primary Registry in the Netherlands.

Dissemination

At the minimum, the results of this study will be published in international peer-reviewed scientific journals. A lay summary of the results will be published as well and send to participants if they are interested.

DISCUSSION

This innovative study aims to manipulate communication to determine how expectations and empathy can lead to placebo-effects and help minimize patients' post-operative pain (among other outcomes). The results can help to shed more light on how communication can be used alongside medical care to enhance patients' outcomes for the better.

That being said, manipulating communication in clinical care poses methodological, ethical and logistical challenges. The success of the study will depend on the success of the delivery of the manipulations. To ensure communication differs between the various groups, and to avoid contamination, all nurses have been trained and the research team is available (on and offsite) for questions, practice, and feedback. On most intervention days, a member of the research team is present at the daycare ward. This is much appreciated by nurses, and ensures that the appropriate manipulation is often practiced before a patient is admitted. Throughout an intervention day, the signposting of all systems (ward lists/hardcopy patient records) and the appropriate pocket cards with examples also serve as a constant reminder of the group allocation. The success of the manipulation is checked using the audio-recordings of nursing interactions and will assist in interpreting our results. While varying communication, the ethical boundaries of not providing any suboptimal communication are and will be clearly adhered to and are stressed in contacts with involved health care professionals. Last, patients come in contact with many clinicians before and during hospitalization. Informing all clinicians and ensuring all but

23

1
2
3 the daycare ward nurses will standardize their communication is crucial to ensure causal
4 effects of the manipulated communication can be determined. Therefore, both the
5 research and clinical team involved have ensured many contact moments with clinicians
6 to personally inform them about the study and appropriate information material has been
7 circulated at study start.
8
9

10
11
12
13
14 Of course, this study is beforehand not without limitations. Most importantly, due to the
15 clinical nature of the study it is impossible to standardize communication elements
16 beyond expectancy and empathy. We did, however, instruct nurses to vary only the
17 manipulated communication and keep the remaining care and communication standard.
18 We therefore believe these elements to not differ widely, but if evenly, between
19 conditions. Moreover, time-differences between the conditions could potentially occur.
20 We did, however, tried to ensure that the manipulations differed as minimally as possible
21 in time (e.g. enhanced empathy consists of little time-consuming behaviors such as sitting
22 opposed to standing) and all interventions need to be delivered within nurses' standard
23 work time. We therefore believe to have minimized the risk for time-differences to occur
24 between conditions. That being said, we acknowledge it remains a limitation of this
25 complex clinical study that due to focus- and power-constraints we will not measure or
26 control for all variables beyond, and time-differences between, the manipulations. A last
27 limitation is that nonverbal behavior (e.g. eye contact) cannot be taken into account when
28 determining adherence to the protocol using the audiotapes.
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 Despite these challenges and limitations, we believe this study is of utmost importance to
44 bring the field of communication and pain research forward. Without conducting
45 controlled studies into the effect of communication, communication will always remain a
46 soft-sided add-on. In order to overcome this, we would recommend future studies to also
47 include biological and clinical outcomes. Most importantly, we hope this study and
48 detailed protocol will provide an impetus for further work in this important area turning
49 communication from 'art to science'.
50
51
52
53
54
55
56
57
58
59
60

24

Authors' contributions

JB is the Chief Investigator.

JB developed the initial concept of the study, supported by SvD and LV

LV, JB, SvD, and SI led on the protocol development, while all authors provided input for the trial design and protocol.

MG, BT, and GvD led on the standardization of hospital routine, pain protocol and medical content.

LV and SI (as of August 2016 also supported by MK, while SI left the project in 2017) lead on the daily management of the trial, supported by MG, BT, GvD, SvD and JB

All authors have read, contributed and approved the final manuscript.

Acknowledgements

We thank Peter Spreeuwenberg for his help with the data analysis plan and power calculation. We thank the clinicians working at the daycare ward, the operation theater, the PACU and at the ENT and Anesthesia department for their help in facilitating the study logistics. We especially thank the daycare ward nurses for delivering the intervention.

Funding

The study is funded by the Spinoza Prize from the Dutch Research Council awarded to Prof. dr. Jozien M. Bensing.

LV is partly funded by a grant from the Foundation for the Science of the Therapeutic Encounter (F-STE).

The funder had no role in the study design and decision to submit the report for publication. The funder will have no role in the collection, management, analysis and interpretation of data or writing and publication of future publications.

Competing interest

25

None declared

Legends

Figure 1. Study design.

Reference list

1. Miller FG, Kaptchuk TJ. The power of context: reconceptualizing the placebo effect. *J R Soc Med* 2008;101:222-25.
2. Finniss DG, Kaptchuk TJ, Miller F, et al. Biological, clinical, and ethical advances of placebo effects. *Lancet* 2010;375:686-95.
3. Turner JA, Deyo RA, Loeser JD, et al. The importance of placebo effects in pain treatment and research. *JAMA* 1994;271:1609-14.
4. Kaptchuk TJ, Miller FG. Placebo effects in medicine. *NEJM* 2015;373:8-9
5. Tracey I. Getting the pain you expect: mechanisms of placebo, nocebo and reappraisal effects in humans. *Nat Med* 2010;16:1277-83.
6. Mistiaen P, van Osch M, van Vliet L, et al. The effect of patient-practitioner communication on pain: a systematic review. *Eur J Pain* 2016;5:675-688..
7. Benedetti F, Maggi G, Lopiano L, et al. Open versus hidden medical treatments: The patient's knowledge about a therapy affects the therapy outcome. *Prevention & Treatment* 2003;6:1a.
8. Charlesworth JE, Petkovic G, Kelley JM, et al. Effects of placebos without deception compared with no treatment: A systematic review and meta-analysis. *J Evid Based Med* 2017;10:97-107
9. Jubb J, Bensing JM. The sweetest pill to swallow: How patient neurobiology can be harnessed to maximise placebo effects. *Neurosci Biobehav Rev* 2013;37:2709-20.
10. Kaptchuk TJ, Kelley JM, Conboy LA, et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. *BMJ* 2008;336:999-1003.
11. Bensing JM, Verheul W. The silent healer: the role of communication in placebo effects. *Patient Educ Couns* 2010;80:293-99.
12. Verheul W, Sanders A, Bensing J. The effects of physicians' affect-oriented communication style and raising expectations on analogue patients' anxiety, affect and expectancies. *Patient Educ Couns* 2010;80:300-06.
13. van Osch M, van Dulmen S, van Vliet L, et al. Specifying the effects of physician's communication on patients' outcomes: A randomised controlled trial. *Patient Educ Couns* 2017;100:1482-9.
14. Manias E, Botti M, Bucknall T. Observation of pain assessment and management- the complexities of clinical practice. *J Clin Nurs* 2002;11(6):724-33
15. Breivik H, Borchgrevink P, Allen S, et al. Assessment of pain. *Br J Anaesth* 2008;101:17-24

26

16. Nederlandse Vereniging voor Anesthesiologie [Dutch Association for Anaesthesiology].. Richtlijn Postoperatieve pijn [Guideline for postoperative pain]. Utrecht, the Netherlands: 2012
17. Petersen GL, Finnerup NB, Groesen K, et al. Expectations and positive emotional feelings accompany reductions in ongoing and evoked neuropathic pain following placebo interventions. *Pain* 2014;155:2687-98.
18. Devilly GJ, Borkovec TD. Psychometric properties of the credibility/expectancy questionnaire. *J Behav Ther Exp Psychiatry* 2000;31:73-86.
19. Lehmann N, Joshi G, Dirkmann D, et al. Development and longitudinal validation of the overall benefit of analgesia score: a simple multi-dimensional quality assessment instrument. *Br J Anaesth* 2010;105:511-18
20. Mercer SW, Maxwell M, Heaney D, et al. The consultation and relational empathy (CARE) measure: development and preliminary validation and reliability of an empathy-based consultation process measure. *Fam Pract* 2004;21:699-705
21. Spielberger CD, Gorsuch RL, Lushene R, et al. State-trait anxiety inventory for adults: sampler set: manual, test, scoring key. Palo Alto, CA: Mind Garden Consulting Psychologists Press
1983.
22. Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. *J Pers Soc Psychol* 1988;54:1063-70.
23. van Kessel P, Hendriks M, van der Hoek L, et al. CQ Index Chronisch Hartfalen. Ontwikkeling van de vragenlijst en de ervaringen van mensen met chronisch hartfalen met de ziekenhuiszorg. [CQ Index Chronic heart failure. Development of the questionnaire and the experiences of chronic heart failure patients with hospital care]. Utrecht, the Netherlands: NIVEL 2015.
24. Van Weel C. Functional status in primary care: COOP/WONCA charts. *Disabil Rehabil* 1993;15:96-101
25. Van Weel C, Konig-Zahn C, Touw-Otten F, et al. Measuring functional status with the COOP/WONCA Charts. A manual. Groningen, the Netherlands: Noordelijk Centrum voor Gezondheidsvraagstukken (NCG)/Northern Centre of Health Care Research (NCH) 2012
26. Davis MH. Measuring individual differences in empathy: evidence for a multidimensional approach. *J Pers Soc Psychol* 1983;44:113-126.
27. Sim J, Wright CC. The kappa statistic in reliability studies: use, interpretation, and sample size requirements. *Phys Ther* 2005;85:257-68.
28. Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics* 1977:159-74.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1. Study design.

		Expectancy	
		enhanced	standard
Empathy	enhanced	Group 1	Group 2
	standard	Group 3	Group 4

209x296mm (300 x 300 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	__1__
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	__3__
	2b	All items from the World Health Organization Trial Registration Data Set	__NA-registered at the Dutch Trial Register__
Protocol version	3	Date and version identifier	__NA, Not in article, __
Funding	4	Sources and types of financial, material, and other support	__24__
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	__1-2__
	5b	Name and contact information for the trial sponsor	__24__
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	__24__

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	____NA, a collaboration agreement between the hospital (OLVG) and NIVEL has been created_____
Introduction			
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	__4-6_____
	6b	Explanation for choice of comparators	__4-6_____
Objectives	7	Specific objectives or hypotheses	__5-6_____
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	__6_____
Methods: Participants, interventions, and outcomes			
Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	__6_____
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	__7_____
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	__9-12_____
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	__12,7_____
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	__9-12 19,20_____

	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	__20,21, 6,_____
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	__12-20_____
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	__8,9,11,12-19____
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	__7- 8_____
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	__8_____

Methods: Assignment of interventions (for controlled trials)

Allocation:

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	__8- 9_____
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	__8- 9_____
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	__8- 9_____
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	__11-12, 9_____
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	__12_____

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Methods: Data collection, management, and analysis

Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	_12-20_____
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	_21,7_____
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	_21_____
Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	_19_____
	20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	_20_____
	20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	_19_____

Methods: Monitoring

Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	_NA, no DMC has been set up_____
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	_NA, no interim analyses are performed_____
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	_21_____

1				
2				
3	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	__NA__
4				
5				
6	Ethics and dissemination			
7				
8	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	__21__
9				
10				
11	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	__21__
12				
13				
14				
15	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	__8,12__
16				
17				
18				
19		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	__NA__
20				
21				
22	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	__21__
23				
24				
25	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	__24-25__
26				
27				
28	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	__21__
29				
30				
31	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	__12__
32				
33				
34	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	__22__
35				
36				
37				
38		31b	Authorship eligibility guidelines and any intended use of professional writers	__NA – ICMJE criteria will be used__
39				
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

31c Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code NA

Appendices

Informed consent materials 32 Model consent form and other related documentation given to participants and authorised surrogates Not provided in article

Biological specimens 33 Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable NA

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.

For peer review only

BMJ Open

Examining the effects of enhanced provider-patient communication on post-operative tonsillectomy pain: protocol of a Randomized Controlled Trial performed by nurses in daily clinical care.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-015505.R2
Article Type:	Protocol
Date Submitted by the Author:	25-Sep-2017
Complete List of Authors:	van Vliet, Liesbeth; NIVEL (Netherlands Institute for Health Services Research), Department of Communication van Dulmen, Sandra; NIVEL, Department of Communication; Radboud University Medical Center, Department of Primary and Community Care Thiel, B; OLVG Hospital, Department of Anesthesiology van Deelen, G; OLVG Hospital, Department of ENT Immerzeel, S; NIVEL, Department of Communication Godfried, M; OLVG Hospital, Department of Anesthesiology Bensing, Joziën; NIVEL, Department of Communication
Primary Subject Heading:	Communication
Secondary Subject Heading:	Anaesthesia
Keywords:	communication, placebo-effects, Pain management < ANAESTHETICS, tonsillectomy, randomized controlled trial

SCHOLARONE™
Manuscripts

1

Title page

Title: Examining the effects of enhanced provider-patient communication on post-operative tonsillectomy pain; Protocol of a Randomized Controlled Trial performed by nurses in daily clinical care.

Van Vliet, van Dulmen, Thiel, van Deelen, Immerzeel, Godfried, Bensing

Corresponding author:

Dr Liesbeth M van Vliet

NIVEL (Netherlands institute for health services research), Department of Communication

P.O.Box 1568

3500 BN Utrecht

The Netherlands

Email: l.vanvliet@nivel.nl

Telephone number: 0031 30 27 29 632

Prof. dr. Sandra van Dulmen

1. NIVEL, Department of Communication

Utrecht, the Netherlands

Email: S.vandulmen@nivel.nl

2. Department of Primary and Community Care, Radboud University Medical Center, Nijmegen, the Netherlands

3. Science Centre Health and Technology, Faculty of Health Sciences, University College of Southeast Norway, Drammen, Norway

Bram Thiel MSc

OLVG Hospital, Department of Anesthesiology

Amsterdam, the Netherlands

Email: B.Thiel@olvg.nl

Dr G. W. van Deelen

Protocol article Clinical study Spinoza Revised Manuscript Clean Copy V2.0 21092017

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

2

OLVG Hospital, Department of ENT
Amsterdam, the Netherlands
Email: G.W.vanDeelen@olvg.nl

Stephanie Immerzeel MSc
NIVEL, Department of Communication
Utrecht, the Netherlands
Email: S.Immerzeel@nivel.nl

Dr Marc B Godfried
OLVG Hospital, Department of Anesthesiology
Amsterdam, the Netherlands
Email: M.B.Godfried@olvg.nl

Prof. dr. Jozien M Bensing
NIVEL, Department of Communication
Utrecht, the Netherlands
Email: j.bensing@nivel.nl

Word count: 5390

Number of Figures: 1

Number of Tables: 1

Number of References: 28

Key words: Communication, placebo-effects, pain management, tonsillectomy,
randomized controlled trial

3

Abstract

Introduction: Placebo effects (true biopsychological effects not attributable to the active ingredients of medical technical interventions) can be attributed to several mechanisms, such as expectancy manipulation and empathy manipulation elicited by a provider's communication. So far, effects have primarily been shown in laboratory settings. The aim of this study is to determine the separate and combined effects of expectancy manipulation and empathy manipulation during pre- and post-operative tonsillectomy analgesia care on clinical adult patients' outcomes.

Methods and analysis: Using a two by two randomized controlled trial 128 adult tonsillectomy patients will be randomly assigned to one out of four conditions differing in the level of expectancy manipulation (standard versus enhanced) and empathy manipulation (standard versus enhanced). Daycare ward nurses are trained to deliver the intervention, while patients are treated via the standard analgesia protocol and hospital routines. The primary outcome, perceived pain, is measured via hospital routine by a Numeric Rating Scale, and additional pre-, peri- and post-hospitalization questionnaires are completed (until day 3, i.e. 2 days after the operation). The manipulation is checked using audio-recordings of nurse-patient interactions.

Ethics and dissemination: Although communication is manipulated, the manipulations do not cross norms or values of acceptable behavior. Standard medical care is provided. The ethical committee of the UMC Utrecht and the local OLVG hospital committee approved the study. Results will be published via (inter)national peer-reviewed journals and a lay publication.

Registration details: NTR5994 (Dutch Trial Register)

Strengths:

- This study is a RCT on the (placebo) effects of communication on top of standard medical care, building the evidence-base of communication.

Limitations:

- The success of the intervention will depend on the ability of nurses to carry out the different communication styles successfully.

INTRODUCTION

In clinical care, patients' outcomes are not only influenced by the active ingredients of drugs or other medical technical interventions, but also by the context in which care is delivered. Such biopsychosocial effects on patients' outcomes that are not attributable to the active ingredients of treatments or interventions are called 'non-specific' or 'placebo-effects'[1 2]. They are real and robust, occurring on top of natural history and regression to the mean[3], and can be observed alongside 'sham-treatments' as well as 'real treatments'[4].

Several mechanisms underlie the generation of placebo-effects on patient outcomes such as pain[5]. A well-understood mechanism is the manipulation of expectations. According to a recent systematic review of our research group, manipulating patients' expectations seems capable of influencing clinical patients' pain perceptions[6]. For example, the verbal suggestion that a drug is an active pain killer is more effective than receiving the same dosage medication without such a suggestion[7]. Manipulating expectations also contribute to the recent described positive effects of open-label placebos (inert treatments being described as such)[8]. A less-well understood mechanism is the communication of empathy in health care professional-patient encounters. Only few scholars have pointed out the potential role of the professional-patient relationship in explaining placebo-effects[9-11]. In our systematic review, we found that empathy had a less strong effect on pain compared to expectations[6]; but studies used different empathy operationalization and empathy was often manipulated together with other elements of the clinical encounter, making it difficult to draw strong conclusions from empathy[6].

When looking at these mechanisms, it seems reasonable that health care professionals' communication can influence them, and can thus produce placebo-effects. Until recently, however, the entities of communication and placebo-effects have hardly been integrated[11]. Communication is traditionally associated with 'art, not science' and placebos with 'evidence-based medicine' in which their effects are typically ruled out by the study design of randomized controlled trials (RCTs).

5

The tide is changing. A landmark-study led by Kaptchuk et al 2008[10] found that placebo-acupuncture delivered with high outcome expectations and an empathic approach led to statistically and clinically significant improvements in the functioning of patients with irritable bowel syndrome compared to placebo-acupuncture delivered without expectations and empathy. The distinct and combined effects of both mechanism, and the effects alongside an active treatment remain, however, unknown from this study.

Our research group has started to unravel the potential separate and combined effects of both expectancy manipulation and empathy manipulation in highly controlled settings. Using scripted video-vignettes and role-play studies, we found that expectancy mainly influences cognitive outcomes (e.g. expected treatment effect) and empathy mainly affective outcomes (e.g. anxiety). The largest positive effects were found when the two elements were combined and a physician raised high expectations meanwhile communicating in a warm, empathic manner[12 13]. However, whether these distinct and combined effects also translate to the clinical setting, alongside an active intervention remains, as yet, an unanswered question. Answering this question is important, as it will provide insight into how specific communication elements can influence specific health outcomes.

Study objective

This study therefore aims to disentangle the role of communication in eliciting placebo-effects in the clinical setting within the context of standard medical care. More specifically, the objective is to determine the separate and combined effects of expectancy manipulation (standard versus enhanced) and empathy manipulation (standard versus enhanced) during pre- and post-operative tonsillectomy analgesia care on clinical adult patients' outcomes (main outcome measure is pain perception). This will be studied using a 2 by 2 RCT design. By following this approach the evidence base on the effects of expressed outcome expectancy and conveyed empathy will be built in clinical care.

Accompanying the study objective, the goals of this study are in subsequent order:

6

1. To examine whether adult patients following tonsillectomy in the enhanced outcome expectancy condition will experience less pain (and other outcomes), compared to patients in the standard condition.
2. To examine whether adult patients following tonsillectomy in the enhanced empathy communication condition will experience less pain (and other outcomes) compared to patients in the standard empathy communication condition.
3. To examine the interaction effects of the different levels of outcome expectancy and empathy on adult patients' experiences of pain (and other outcomes).

METHODS AND ANALYSIS

Design and setting

A four-arm (2 by 2 design) single-blind randomized controlled trial will be conducted at the daycare nursing wards on two locations of a Dutch general hospital (OLVG Amsterdam), in which adult tonsillectomy patients are pre- and postoperatively monitored and treated by nurses. Patients will be randomly assigned to one out of 4 arms, which vary in the induction of expectations (standard vs enhanced), and (the level of) nurses' communication of empathy (standard vs enhanced). Depending on the patient's allocation, nurses will express a standard or enhanced outcome expectation of patients' pain, and provide care in a standard or enhanced empathic manner. See figure 1 for the study design. All patients will be treated according to the usual analgesic treatment protocol and daily routine care of the hospital. Recruitment started in August 2016 and will presumably continue until early 2018.

Patients

This study focuses on adult tonsillectomy patients. This population was carefully selected as it is a homogeneous population. These patients are young adults, generally aged 18-35, without complex comorbidity (ASA 1) and lack a history of chronic pain. Moreover, tonsillectomy is generally accepted as a strong confound nociceptive trigger resulting into high levels of postoperative pain that only lasts for a relatively short period of time (1-2 weeks).

7

Inclusion criteria

In order to be eligible to participate in this study, a patient must meet the following criteria:

- Scheduled for tonsillectomy in daycare
- ≥ 18 years of age
- Speaking and understanding of the Dutch language
- Having mental capacity

Exclusion criteria

A potential patient who meets the following criteria will be excluded from participation in this study:

At study start (during inclusion process):

- Not scheduled for tonsillectomy in day care
- < 18 years of age
- Not speaking and understanding of the Dutch language
- Lacking mental capacity (cognitive decline, dementia)

During the course of the study:

- Patients who experience a post-operative bleeding will be excluded.
- The health care professionals involved and research team can decide to withdraw a patient from the study for urgent medical reasons (e.g. if patients are not discharged on the day of operation due to complications).

If a patient drops-out, data until exclusion will be included in the analyses unless the patient objects to this (this will be asked upon exclusion).

Sample size

The sample size calculation is based on the primary outcome, i.e. pain. This calculation is based on a previous similar study[7], in which an open versus hidden administration of analgesic showed a difference of 1.2 and a total variance of 2.18. Based on a power of .80

8

and alpha of .05, and including an interaction-effect (with a within variance of 1.92), this results in a needed sample size of 32 patients per arm and $4 \times 32 = 128$ patients in total.

Recruitment

The recruitment of patients occurs in several steps:

- i) Patients are approached for the study while discussing the operation with their consulting ear nose and throat specialist (i.e. ENT doctor). All eligible and interested patients are provided with a Patient Information Folder (PIF) and informed consent form. The PIF omits specific study aims, but mentions that communication will be manipulated. It is stressed that participation is free of choice and will not affect usual medical care.
- ii) During the pre-operative examination, which is mostly conducted within a few days of the ENT consultation, the anaesthesiology clinician asks whether the patient is informed about the study. If not, they will provide them the PIF and consent form. They will ask whether the patient is interested in participation and whether the research team can call the patient to provide them with more information. This response is noted in the electronic record and transferred to the researchers via an (automated) email.
- iii) The research team will call the patient, explain the study in more detail and ask the patient to return the completed informed consent form.

Patients who are already planned for surgery when the study opens (the normal time between ENT consultation and the operation is 6-8 weeks) will be called by involved health care practitioners (from the ENT/Anaesthesiology department). They are informed about the study via telephone. In case they are interested, their name and telephone number are transferred to the researchers. The researchers will call the patient, and send them an information letter and consent form which participants can complete and return in case they are willing to participate.

Randomization

Upon providing informed consent patients are randomized using a random number generator (1:1:1:1: allocation rate). Assignments will be provided via sequentially

9

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

numbered opaque sealed envelopes. A secretary not otherwise involved in the study will open the assignment envelopes.

After patients are randomized, the research team will inform the health care professionals about their inclusion. They will insert this information in the medical records of the hospital system (EPIC). Moreover, they will inform the day care administrators and key contact persons about the patients that are scheduled in the upcoming week or days and which condition they are randomized to. On the day of admission, the researchers will ensure that all appropriate systems (e.g. the ward lists and the hard copy patient records) are adequately signposted with the patients' condition. We will use color codes for this to avoid unblinding patients. Only one patient per room is included at any time point.

Intervention

The intervention consists of a (protocolled) communication manipulation on top of standard analgesic treatment. Nurses at the day care ward will incorporate an (protocolled) expectancy manipulation (standard versus enhanced) related to the effects of the pain medication and empathy manipulation (standard versus enhanced) into their communication. The communication intervention will be provided at all nurse-patient communication moments during patients' stay at the day care ward (pre- and post-operation, day 1, the daycare wards are open between 7AM-6PM and 6.45AM-7PM respectively), and during the nurses' telephone consultation with patients the day post-discharge (day 2). In practice, this means that all communication patients receive from daycare ward nurses during this time frame will be according to patients' assigned condition. This includes interactions during intake, pain assessments, medication allocation, and transferal to the operation theater and from the post anesthesia care unit (PACU), discharge, and all other interactions due to patients' questions or medical need.

All nurses will receive training to ensure their ability to perform the different communication manipulations. We will make use of a professional trainer and comprehensive training protocol including scripts (i.e. written examples), video-examples, and role-play. Moreover, posters are placed in the communal spaces for nurses with

10

1
2
3 information about the study; e.g. examples of the manipulations and study procedures.
4
5 Pocket cards with examples of the manipulations are provided. To ensure the
6
7 communication differs between the 4 conditions and to minimize carry-over effects (e.g.
8
9 nurses' stressing enhanced expectations display automatically an enhanced empathy
10
11 style), the 4 conditions are trained separately and the posters and pockets cards focus on
12
13 the 4 different conditions. The importance of the manipulations being successful in order
14
15 to draw conclusions from the found results is stressed during the training day.
16

17 18 *Expectancy manipulation*

19
20 In the standard condition nurses do not aim to create the expectation that the pain
21
22 medication will work very well. They might use sentences such as "The medications
23
24 attempt to reduce your pain ever so slightly", or "This is your pain medication".
25

26
27 In the enhanced condition nurses aim to create the expectation that the pain medication
28
29 will work very well. They might use sentences such as: "The medications I am giving you
30
31 now will lead to a strong decrease of your pain", or "This pain medication is known for
32
33 working very well".
34

35 36 *Empathy manipulation*

37
38 In the standard condition nurses aim to create a neutral atmosphere which is standard.
39
40 They will be trained to (amongst other behavior) keep standing when communicating
41
42 with patients, react with standard empathy to patients' cues and concerns, not explore
43
44 concerns in detail, to not express extra interest in the patient as a person, to not pay extra
45
46 attention to not interrupting patients, and to not make extra eye contact.
47

48
49 In the enhanced condition, nurses aim to create an atmosphere, which is extra warm and
50
51 extra friendly. They will be trained to (amongst other behavior) introduce themselves
52
53 properly, sit while communicating with patients, react extra empathically to patients' cues
54
55 and concerns (verbal and nonverbal) and take their concerns seriously, to show extra
56
57 interest in the patient as a person, to not interrupt the patient, and to make adequate eye
58
59 contact.
60

11

1
2
3
4
5 It should be noted that the communication manipulation does not cross important norms
6 or values of acceptable behavior and that the psychological integrity of patients will not be
7 harmed. An observational study among clinical postsurgical patients showed that nurse-
8 patient interactions are often subject to interruptions related to other tasks e.g. searching
9 for equipment, answering telephone calls, or being interrupted by other
10 professionals[14]. The interruptions and nurses' attempts to address competing demands
11 impact on the time and attention spent with patients. It can therefore be assumed that
12 variations in communication are inherently due to clinical encounters. This was also
13 confirmed by field observations conducted by the research team before study start. The
14 aforementioned developed scripts/examples which are used in the training have been
15 commented upon by nurses and researchers in a pilot study to ensure they are realistic
16 and do not trespass ethical boundaries and have been finalized in collaboration with
17 involved clinicians.

30 *Standardizing of communication*

31
32 The communication patients receive from other clinicians involved during their
33 hospitalization (e.g. from the surgical team working in the operation theater and the
34 clinical team working in the PACU) will be standardized as much as possible. Also the
35 communication during the pre-operative ENT and Anaesthesiology visit will be
36 standardized as much as possible. Involved health care professionals will be informed of
37 the study aims and the importance to keep their communication neutral (if possible) (i.e.
38 to not provide extra empathy or raise extra expectations about pain) for included patients.
39 This is feasible, as the ENT and anesthesiology team are involved in the study, and it is
40 uncommon for patients to ask about pain medication during their time at the PACU.

50 *Blinding*

51 Patients will be blinded to the specific study aims and treatment allocation.
52
53 The involved health care personnel cannot be blinded. All health care personnel involved
54 will receive clear and specific instructions about informing and including patients to
55 preserve experimental control. Besides, all interactions within the study between nurses
56
57
58
59

12

and patients will be audio-recorded to evaluate the fidelity of the communication manipulation.

Study procedure

After receiving informed consent, the research team will send a baseline questionnaire to the patient. Completion of this questionnaire will be done at home and will take no more than 20 minutes. Post-operatively (at daycare, day 1) a short (5-minute) questionnaire is administered. As part of routine care, pre- and post- operatively, patients rate their level of pain. At day 2 (the day after discharge) patients will complete another questionnaire about their pain and medication use. At day 3 a last questionnaire will be completed which will take 20 minutes. Patients are given the choice between paper and pencil and online completion of questionnaires. This timeframe of follow-up is chosen as we expect the effect of the intervention (delivered within a few hours by daycare ward nurses solely) to wane within a few days.

Moreover, the interactions between involved nurses and included patients will be recorded. Nurses will be provided with a portable audio-recording device with microphone. During every visit, the nurses will mention patient's identification number by means of reference, to protect patients' privacy. At day 4 (3 days after discharge) patients will receive a debriefing letter by postal mail which will inform them about the study aims and their assigned condition. If they wish to receive more information they can contact the research team.

Withdrawal of individual patients

Patients can leave the study at any time for any reason if they wish to do so without any consequences. The health care professionals involved and research team can decide to withdraw a patient from the study for urgent medical reasons (e.g. a bleeding after operation). If a patient drops-out, the research team is informed of this. Patients will continue to receive standard medical care and communication.

Informed consent nurses

13

1
2
3 Nurses involved in the study will be asked to participate as participants using an
4 information sheet and a consent form. They will be asked to complete the consent form
5 and a questionnaire about their background characteristics. We will offer them, at study
6 end, participation in a (accredited) communication training to thank them for their
7 participation in this project.
8
9
10
11
12

13 **Outcomes**

14 *Main study outcome:*

- 15 • Pain perception/intensity

16 As part of routine care, during hospitalization and post-hospitalization patients' pain will
17 be assessed on the basis of a Numeric Rating Scale (NRS) (0-10), ranging from 'no pain' to
18 'worst imaginable pain' [15 16]. Pain is rated preoperatively at daycare ward, at the PACU
19 , and postoperatively at daycare ward. On study day 2, one day after discharge, daycare
20 ward nurses will contact the patients by telephone and again assess their pain. On top of
21 this standard routine, pain is assessed at home on day 2 and day 3 (study end).
22
23
24
25
26
27
28
29
30
31

32 *Secondary study outcome*

33 In the patient questionnaires, the following secondary outcomes will be assessed:

- 34 • Pain expectations

35 Patients' pain expectations are measured using two items (both measured using a self-
36 created Visual Analogue Scale (VAS); i) Patients' pain expectations for the few days
37 following the operation (VAS ranging from 'no pain' to 'the most intense pain imaginable',
38 ranging from 0-10, adapted from Petersen et al., 2014[17]); ii) Patients' expectations of
39 improvement in pain following receiving pain medication (VAS ranging from '0%
40 improvement' (no improvement) to '100% improvement' (most improvement
41 imaginable), adapted from the Credibility and Expectancy Questionnaire (CEQ)[18]. These
42 questions will be assessed post-operatively (during hospitalization).
43
44
45
46
47
48
49
50
51

- 52 • Overall benefit of analgesia

53 The overall benefit of analgesia score (OBAS) will be assessed[19]. The OBAS is a
54 multidimensional 7-item instrument in which patients indicate (on a 0-4 scale, ranging
55 from 'not at all' to 'very much') the level of current pain and distress arising from several
56
57
58
59
60

14

1
2
3 symptoms such as itch. The OBAS is measured post-hospitalization (at home) at day 2 and
4
5 3 (study end).
6

- 7 • Analgesic dosage

8
9 The total dosage of administered analgesics will be assessed during hospital stay and
10 noted in the medical record. The total dosage of administered analgesic at home post-
11 operation will be assessed at day 2 and 3 (study end) by asking patients to indicate which
12 pain medication they use/have used.
13

- 14 • Analgesic request by a patient

15
16 Analgesic request will be assessed during hospital stay and noted in the medical record.
17

- 18 • Perceived empathy

19
20 Perceived empathy will be determined using the Consultation and Relational Empathy
21 Measure (CARE)[20] in which the term 'doctor' is replaced with 'nurse' and 'consultation'
22 is replaced with 'contact' (10 items, 1-5 scale ranging from 'poor' to 'excellent' (and 'not
23 relevant'), e.g. "How was the nurse at showing care and compassion"). Perceived empathy
24 is measured at day 3 (study end).
25

- 26 • Perceived expectation

27
28 We will measure the extent to which participants thought nurses had induced the
29 expectation that medication would be effective to decrease their pain. This will be
30 assessed using a 1-item self-created VAS scale ('no effect at all' to 'a lot of effect', ranging
31 from 0-10). Perceived expectation will be measured at day 3 (study end).
32

- 33 • State anxiety

34
35 Patients' level of anxiety will be measured by the Dutch 10-item State measure of the
36 State-Trait Anxiety Inventory (STAI-State)[21](1-4 scale ranging 'not at all' to 'very
37 much'). Patients' anxiety is assessed pre-hospitalization, and at day 3 (study end).
38

- 39 • Mood

40
41 Mood will be measured using the Positive and Negative Affect Schedule (PANAS)[22] (20-
42 items, 1-5 scale ranging from 'not at all' to 'very much' e.g. "I am excited" or "I am upset").
43 Mood is measured pre-hospitalization, and at day 3 (study end).
44

- 45 • Satisfaction

15

Participants' satisfaction with the provided care by the nurses during daycare will be assessed using a 1-item self-created VAS scale ('not at all' to 'very much', 0-10 range). Satisfaction will be measured at day 3 (study end).

- General pain evaluation

Whether the pain following the operation has been better or worse than expected, will be measured using a 1-item self-created VAS scale (ranging from 'much worse than expected' to 'much better than expected', 0-10 range). Pain evaluation is measured at day 3 (study end).

- General evaluations regarding hospitalization

Patients' evaluations of their hospitalization are measured using two items i) How likely it is that the patient would recommend this hospital to other tonsillectomy patients (using an adapted item from the CQ Index[23] (0-10 scale 'would definitely not recommend' to 'would definitely recommend'); ii) Their overall rating of the quality of care provided by the hospital during hospitalization, using an adapted item from the CQ Index[23](0-10 scale, 'very poor care' to 'extremely good care'). This is measured at day 3 (study end).

Other outcomes

The following background characteristics of patients are measured pre-hospitalization;

- Socio-demographics

E.g. date of birth, gender, marital status, education, ethnicity, societal position, and date of operation.

- Functional health status

Measured using the COOP-WONCA; 7-item scale assessing several health status elements, e.g. physical fitness, on a 1-5 scale ranging from "not limited at all" to 'severely limited'[24 25].

- General experiences/expectations/attitudes medications

We will measure the extent to which patients generally i) benefit from, ii) have positive expectations towards the effect of, iii) have objections against taking medicines. This will be done using self-created VAS scales (ranging from 'not at all' to 'very much', 0-10 range).

- General reporting of pain

16

We will measure whether patients generally are inclined to report their pain using a self-created VAS scale (ranging from 'never' to 'always', 0-10 range)

- Attitudes towards operation

The extent to which participants i) are dreading, and ii) are afraid of the operation will be measured using two self-created VAS scales (ranging from 'not at all' to 'very much', 0-10 range).

In addition, we will measure:

- Data medical record

We will ask patients' permissions to access the medical record. We will routinely use medical background data (diagnosis, weight, prescribed medication) and analgesic information (as aforementioned). If needed, additional data will be screened for (e.g. in cases of outlier data the medical record might provide useful information).

Background measures for nurses

The following nurses' characteristics will be measured at study start.

- Socio-demographics

E.g. date of birth, gender, and type of nurse (i.e. nurse in training, regular nurse, specialized nurse).

- Empathy personality trait:

We will measure nurses' empathic abilities using the Interactive Reactivity Index (IRI)[26]. The IRI consists of 28 items (e.g. "I often feel sorry for people who are less fortunate than me") which are scored on a 1-5 scale (ranging from 'describes me not at all' to 'describes me very well').

An overview of the measured outcomes at different time points is provided in Table 1.

Domain	Measure	Collected	Pre-hospitalization	Post-operation (at day care, day 1)	During hospitalization (pre-peri-post operative, day 1)	Post-hospitalization (at home, day 2)	Post-hospitalization/study end (at home, day 3)
Pain perception/intensity	Standard hospital NRS	Patient			x	x	x
Pain Expectations	Adapted VAS scale	Patient		x			
Overall benefit of analgesia	OBAS	Patient				x	x
Analgesic Dosage		medical record/patient			x	x	x
Analgesic Request		medical record			x		
Perceived empathy	CARE	Patient					x
Perceived expectation	Self-created VAS	Patient					x
Anxiety	State-anxiety (State)	Patient	X				x
Mood	PANAS	Patient	X				x

Protocol article Clinical study Spinoza Revised Manuscript Clean Copy V2.0 21092017

18

Satisfaction	Self-created VAS scale	Patient					x
General pain evaluation	Self-created VAS Scale	Patient					x
General evaluation about hospitalization	Adapted CQ Index items	Patient					x
Socio demographics		Patient	X				
Functional health status	COOP-WONCA	Patient	X				
General Experiences/Expectations/Attitudes	Self-created VAS scales	Patient	X				
General reporting of pain	Self-created VAS scale	Patient	X				
Attitudes towards operation	Self-created VAS scale	Patient	X				
Data medical record	e.g. Diagnosis, weight, prescribed medication	Medical record	X		X		
Nurse – socio demographics		Nurse	At study start				
Nurse - empathy	IRI	Nurse	At study start				

Protocol article Clinical study Spinoza Revised Manuscript Clean Copy V2.0 21092017

1
2
3
4
5 Table 1 – Overview measured outcomes at different time points
6
7
8

9 *Adherence to the communication manipulation protocol:*

10 To verify the fidelity of the communication manipulation, the interaction between nurses
11 and patients will be audio-recorded. The adherence will be verified by listening back to a
12 random sample (10% of the sample) of audio-recorded visits and to determine the
13 adherence to the protocol (as is comparably done by[10]). Two research assistants who
14 are not otherwise involved in the study will independently evaluate the audio-recordings
15 on adherence to the protocol.
16
17
18
19
20
21

22
23 **Data analysis plan**

24 All data will be analysed using STATA 13.0 with two-sided significance testing at $p < .05$.
25 All available data from patients will be included in the analysis and missing data might be
26 imputed. An intention to treat (ITT) analysis will be performed, thereby also examining
27 selective attrition.
28
29
30
31
32
33

34 *Primary outcomes*

35 Descriptive statistics will be calculated for patients' reported pain intensity (main
36 outcome measure) for the different time points during and post- hospitalization. Since our
37 design consists of a 2 (expectancy: enhanced vs. standard) by 2 (empathy: enhanced vs.
38 standard) design all outcomes will be analysed using either analyses of variance (if
39 focussed on a specific time point) or multilevel repeated measures regression analyses (if
40 focused on different time points which means that several ratings are included for one
41 person). Both communication elements (i.e. expectancy and empathy) are dummy coded.
42 Main effects and interaction effects of expectancy and empathy will be explored. New
43 insights gathered during the analysing process might be examined (if feasible).
44
45
46
47
48
49
50
51
52

53 *Secondary outcomes*

54 Descriptive statistics will be calculated for secondary outcome measures. The effect of our
55 manipulated variables will be analysed using analyses of variance.
56
57
58
59
60

Other outcomes

Frequencies and means will be calculated for the demographics. The four groups will be checked on equality by using chi-squared tests or analyses of variance (ANOVA). If groups differ on specific variables, these variables might be used as control variables in the multilevel analysis.

Adherence to communication protocol

Data of the audio-recordings are observed by trained coders on adherence to the protocol to verify fidelity. First, 10% of the audio-recordings are independently checked on adherence to the protocol. For this purpose, the aforementioned main (verbal) features of the manipulations (see p10) are described and rated for their occurrence when listening to the audio-recordings. Using this it is determined to which of the 4 conditions the audio recording belongs to. Second, inter-rater reliability between the coders of the outcomes will be assessed by calculating Cohen's kappa. Values ranging between 0.21 and 0.41 are considered fair, values between 0.41 and 0.60 moderate and values greater than 0.61 are considered good (i.e. substantial/almost perfect). We consider values as reliable if Cohen's kappa is greater than 0.41[27 28]. Moreover, the number of nurse-patient interactions and duration of interactions is measured for each audio-recording.

ETHICS AND DISSEMINATION

Risks and burden for participants

All participating patients receive usual care with regard to surgery, analgesia and pre- and post-operative treatment. There are no risks associated with this clinical study. The communication manipulation will be provided on top of standard care and is designed in such a way that there will be no harmful effects for patients. Although practitioners' communication is deliberately manipulated and associated with both positive and less positive effects, the communication manipulation does not cross important norms or values of acceptable behavior nor will it affect the psychological integrity of patients. Variations in nurse-patient interactions occur naturally within clinical settings, justifying our approach. Moreover, although patients are informed about the study by their treating

21

1
2
3 clinicians, informed consent will be gathered by the research team. The clinical and
4 research team will stress that participation is voluntary and will not affect standard
5 clinical care. Patients are always free to withdraw their participation in the study. Last, it
6 can be a burden for patients to complete a few additional questionnaires. We attempt to
7 decrease the burden by using short questionnaires and limiting follow-up to 3 days.
8 Results, ultimately, will provide more insight into the effect of communication on patient
9 outcomes.
10
11
12
13
14
15
16
17

18 **Adverse and serious adverse events**

19 All adverse events reported spontaneously by the patient or observed by the clinical or
20 research team will be recorded. All serious adverse events will be reported to the ethical
21 committee who has approved the study and the online database. This will be done within
22 15 days (7 days for the first reporting if an SAE resulted in death or was life threatening).
23 Due to the content of the intervention, we do not expect SAE's to happen. The research
24 team, supported by the clinical team will regularly check the medical records for the
25 occurrence of any adverse events and serious adverse events.
26
27
28
29
30
31
32
33

34 **Confidentiality**

35 Patients' data will be anonymized using an identification number. This code will be
36 safeguarded by an independent contact person at NIVEL and this information will be kept
37 on a protected drive using a protected file independently of the research data. The
38 researchers involved in this study will have access to the research data. The audio-
39 recordings will not be destroyed after the research, but will be added to the NIVEL
40 audio/video database. At present, NIVEL has a database of around 18,000 (digitized)
41 video-recorded and audio-recorded healthcare visits and a well-equipped infrastructure
42 with computerized observation units.
43
44
45
46
47
48
49
50
51

52 **Ethical approval**

53 This study has received ethical approval from the ethical committee of the UMC Utrecht
54 (number 16/144, NL55225.041) and the institutional review board of the participating
55
56
57
58
59
60

22

hospital (number WO 16.506). All amendments will be notified to the ethical committee that gave a favorable opinion.

Trial registration

The study is registered at the Dutch Trial Register (Registration number NTR5994) which is the Primary Registry in the Netherlands.

Dissemination

At the minimum, the results of this study will be published in international peer-reviewed scientific journals. A lay summary of the results will be published as well and send to participants if they are interested.

DISCUSSION

This innovative study aims to manipulate communication to determine how expectations and empathy can lead to placebo-effects and help minimize patients' post-operative pain (among other outcomes). The results can help to shed more light on how communication can be used alongside medical care to enhance patients' outcomes for the better.

That being said, manipulating communication in clinical care poses methodological, ethical and logistical challenges. The success of the study will depend on the success of the delivery of the manipulations. To ensure communication differs between the various groups, and to avoid contamination, all nurses have been trained and the research team is available (on and offsite) for questions, practice, and feedback. On most intervention days, a member of the research team is present at the daycare ward. This is much appreciated by nurses, and ensures that the appropriate manipulation is often practiced before a patient is admitted. Throughout an intervention day, the signposting of all systems (ward lists/hardcopy patient records) and the appropriate pocket cards with examples also serve as a constant reminder of the group allocation. The success of the manipulation is checked using the audio-recordings of nursing interactions and will assist in interpreting our results. While varying communication, the ethical boundaries of not providing any suboptimal communication are and will be clearly adhered to and are stressed in contacts

1
2
3 with involved health care professionals. Last, patients come in contact with many
4 clinicians before and during hospitalization. Informing all clinicians and ensuring all but
5 the daycare ward nurses will standardize their communication is crucial to ensure causal
6 effects of the manipulated communication can be determined. Therefore, both the
7 research and clinical team involved have ensured many contact moments with clinicians
8 to personally inform them about the study and appropriate information material has been
9 circulated at study start.
10
11
12
13
14
15
16

17
18 Of course, this study is beforehand not without limitations. Most importantly, due to the
19 clinical nature of the study it is impossible to standardize communication elements
20 beyond expectancy and empathy. We did, however, instruct nurses to vary only the
21 manipulated communication and keep the remaining care and communication standard.
22 We therefore believe these elements to not differ widely, but if evenly, between
23 conditions. Moreover, time-differences and differences in the number of nurse-patient
24 interactions between the conditions could potentially occur. We did, however, tried to
25 ensure that the manipulations differed as minimally as possible in time (e.g. enhanced
26 empathy consists of little time-consuming behaviors such as sitting opposed to standing)
27 and all interventions need to be delivered within nurses' standard work time. Moreover,
28 we instructed nurses to display the manipulations during all their standard interactions,
29 and did not instruct them to have extra interactions in the enhanced conditions. We
30 therefore believe to have minimized the risk for time-differences and interaction-
31 differences to occur between conditions. For the 10% checked audio-recordings
32 consultation time and the number of nurse-patient interactions are measured, which
33 might help us in interpreting the findings. Still, we acknowledge it remains a limitation of
34 this complex clinical study that due to focus- and power-constraints we will not
35 completely measure or control for all variables beyond, and time-/interaction-differences
36 between, the manipulations. A last limitation is that nonverbal behavior (e.g. eye contact)
37 cannot be taken into account when determining adherence to the protocol using the
38 audiotapes.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

24

Despite these challenges and limitations, we believe this study is of utmost importance to bring the field of communication and pain research forward. Without conducting controlled studies into the effect of communication, communication will always remain a soft-sided add-on. In order to overcome this, we would recommend future studies to also include biological and clinical outcomes. Most importantly, we hope this study and detailed protocol will provide an impetus for further work in this important area turning communication from 'art to science'.

Authors' contributions

JB is the Chief Investigator.

JB developed the initial concept of the study, supported by SvD and LV

LV, JB, SvD, and SI led on the protocol development, while all authors provided input for the trial design and protocol.

MG, BT, and GvD led on the standardization of hospital routine, pain protocol and medical content.

LV and SI (as of August 2016 also supported by MK, while SI left the project in 2017) lead on the daily management of the trial, supported by MG, BT, GvD, SvD and JB

All authors have read, contributed and approved the final manuscript.

Acknowledgements

We thank Peter Spreeuwenberg for his help with the data analysis plan and power calculation. We thank the clinicians working at the daycare ward, the operation theater, the PACU and at the ENT and Anesthesia department for their help in facilitating the study logistics. We especially thank the daycare ward nurses for delivering the intervention.

Funding

The study is funded by the Spinoza Prize from the Dutch Research Council awarded to Prof. dr. Jozien M. Bensing.

25

1
2
3 LV is partly funded by a grant from the Foundation for the Science of the Therapeutic
4 Encounter (F-STE).
5
6
7

8
9 The funder had no role in the study design and decision to submit the report for
10 publication. The funder will have no role in the collection, management, analysis and
11 interpretation of data or writing and publication of future publications.
12
13

14 15 16 **Competing interest**

17 None declared
18
19

20 21 22 **Legends**

23 **Figure 1.** Study design.
24
25
26
27
28

29 30 31 **Reference list**

- 32 1. Miller FG, Kaptchuk TJ. The power of context: reconceptualizing the placebo effect. *J R Soc Med* 2008;101:222-25.
- 33 2. Finniss DG, Kaptchuk TJ, Miller F, et al. Biological, clinical, and ethical advances of
34 placebo effects. *Lancet* 2010;375:686-95.
- 35 3. Turner JA, Deyo RA, Loeser JD, et al. The importance of placebo effects in pain treatment
36 and research. *JAMA* 1994;271:1609-14.
- 37 4. Kaptchuk TJ, Miller FG. Placebo effects in medicine. *NEJM* 2015;373:8-9
- 38 5. Tracey I. Getting the pain you expect: mechanisms of placebo, nocebo and reappraisal
39 effects in humans. *Nat Med* 2010;16:1277-83.
- 40 6. Mistiaen P, van Osch M, van Vliet L, et al. The effect of patient-practitioner
41 communication on pain: a systematic review. *Eur J Pain* 2016;5:675-688..
- 42 7. Benedetti F, Maggi G, Lopiano L, et al. Open versus hidden medical treatments: The
43 patient's knowledge about a therapy affects the therapy outcome. *Prevention &*
44 *Treatment* 2003;6:1a.
- 45 8. Charlesworth JE, Petkovic G, Kelley JM, et al. Effects of placebos without deception
46 compared with no treatment: A systematic review and meta-analysis. *J Evid Based*
47 *Med* 2017;10:97-107
- 48 9. Jubb J, Bensing JM. The sweetest pill to swallow: How patient neurobiology can be
49 harnessed to maximise placebo effects. *Neurosci Biobehav Rev* 2013;37:2709-20.
- 50 10. Kaptchuk TJ, Kelley JM, Conboy LA, et al. Components of placebo effect: randomised
51 controlled trial in patients with irritable bowel syndrome. *BMJ* 2008;336:999-1003.
- 52 11. Bensing JM, Verheul W. The silent healer: the role of communication in placebo effects.
53 *Patient Educ Couns* 2010;80:293-99.
54
55
56
57
58
59

26

12. Verheul W, Sanders A, Bensing J. The effects of physicians' affect-oriented communication style and raising expectations on analogue patients' anxiety, affect and expectancies. *Patient Educ Couns* 2010;80:300-06.
13. van Osch M, van Dulmen S, van Vliet L, et al. Specifying the effects of physician's communication on patients' outcomes: A randomised controlled trial. *Patient Educ Couns* 2017;100:1482-9.
14. Manias E, Botti M, Bucknall T. Observation of pain assessment and management- the complexities of clinical practice. *J Clin Nurs* 2002;11(6):724-33
15. Breivik H, Borchgrevink P, Allen S, et al. Assessment of pain. *Br J Anaesth* 2008;101:17-24
16. Nederlandse Vereniging voor Anesthesiologie [Dutch Association for Anaesthesiology].. Richtlijn Postoperatieve pijn [Guideline for postoperative pain]. Utrecht, the Netherlands: 2012
17. Petersen GL, Finnerup NB, Grosen K, et al. Expectations and positive emotional feelings accompany reductions in ongoing and evoked neuropathic pain following placebo interventions. *Pain* 2014;155:2687-98.
18. Devilly GJ, Borkovec TD. Psychometric properties of the credibility/expectancy questionnaire. *J Behav Ther Exp Psychiatry* 2000;31:73-86.
19. Lehmann N, Joshi G, Dirkmann D, et al. Development and longitudinal validation of the overall benefit of analgesia score: a simple multi-dimensional quality assessment instrument. *Br J Anaesth* 2010;105:511-18
20. Mercer SW, Maxwell M, Heaney D, et al. The consultation and relational empathy (CARE) measure: development and preliminary validation and reliability of an empathy-based consultation process measure. *Fam Pract* 2004;21:699-705
21. Spielberger CD, Gorsuch RL, Lushene R, et al. State-trait anxiety inventory for adults: sampler set: manual, test, scoring key. Palo Alto, CA: Mind Garden Consulting Psychologists Press 1983.
22. Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. *J Pers Soc Psychol* 1988;54:1063-70.
23. van Kessel P, Hendriks M, van der Hoek L, et al. CQ Index Chronisch Hartfalen. Ontwikkeling van de vragenlijst en de ervaringen van mensen met chronisch hartfalen met de ziekenhuiszorg. [CQ Index Chronic heart failure. Development of the questionnaire and the experiences of chronic heart failure patients with hospital care]. Utrecht, the Netherlands: NIVEL 2015.
24. Van Weel C. Functional status in primary care: COOP/WONCA charts. *Disabil Rehabil* 1993;15:96-101
25. Van Weel C, Konig-Zahn C, Touw-Otten F, et al. Measuring functional status with the COOP/WONCA Charts. A manual. Groningen, the Netherlands: Noordelijk Centrum voor Gezondheidsvraagstukken (NCG)/Northern Centre of Health Care Research (NCH) 2012
26. Davis MH. Measuring individual differences in empathy: evidence for a multidimensional approach. *J Pers Soc Psychol* 1983;44::113-126.
27. Sim J, Wright CC. The kappa statistic in reliability studies: use, interpretation, and sample size requirements. *Phys Ther* 2005;85::257-68.

27

28. Landis JR, Koch GG. The measurement of observer agreement for categorical data.
Biometrics 1977:159-74.

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1. Study design.

		Expectancy	
		enhanced	standard
Empathy	enhanced	Group 1	Group 2
	standard	Group 3	Group 4

209x296mm (300 x 300 DPI)



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	__1__
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	__3__
	2b	All items from the World Health Organization Trial Registration Data Set	__NA-registered at the Dutch Trial Register__
Protocol version	3	Date and version identifier	__NA, Not in article, __
Funding	4	Sources and types of financial, material, and other support	__24__
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	__1-2__
	5b	Name and contact information for the trial sponsor	__24__
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	__24__

1
2
3 5d Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint
4 adjudication committee, data management team, and other individuals or groups overseeing the trial, if
5 applicable (see Item 21a for data monitoring committee) _____NA, a
6 collaboration
7 agreement
8 between the
9 hospital (OLVG)
10 and NIVEL has
11 been
12 created_____

13 **Introduction**

14
15 Background and 6a Description of research question and justification for undertaking the trial, including summary of relevant _____4-6_____
16 rationale studies (published and unpublished) examining benefits and harms for each intervention
17
18 6b Explanation for choice of comparators _____4-6_____
19
20 Objectives 7 Specific objectives or hypotheses _____5-6_____
21
22 Trial design 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group),
23 allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) _____6_____
24
25

26 **Methods: Participants, interventions, and outcomes**

27
28 Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will _____6_____
29 be collected. Reference to where list of study sites can be obtained
30
31 Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and _____7_____
32 individuals who will perform the interventions (eg, surgeons, psychotherapists)
33
34 Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when they will be _____9-12_____
35 administered
36
37 11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose _____12,7_____
38 change in response to harms, participant request, or improving/worsening disease)
39
40 11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence _____9-12 19,20_____
41 (eg, drug tablet return, laboratory tests)
42
43
44
45

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	__20,21, 6,_____
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	__12-20_____
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	__8,9,11,12-19____
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	__7- 8_____
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	__8_____

Methods: Assignment of interventions (for controlled trials)

Allocation:

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	__8- 9_____
Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	__8- 9_____
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	__8- 9_____
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	__11-12, 9_____
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	__12_____

Methods: Data collection, management, and analysis

1				
2				
3				
4				
5	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related	_12-20_____
6	methods		processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of	
7			study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known.	
8			Reference to where data collection forms can be found, if not in the protocol	
9				
10				
11		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be	_21,7_____
12			collected for participants who discontinue or deviate from intervention protocols	
13				
14	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality	_21_____
15			(eg, double data entry; range checks for data values). Reference to where details of data management	
16			procedures can be found, if not in the protocol	
17				
18	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the	_19_____
19			statistical analysis plan can be found, if not in the protocol	
20				
21		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	_20_____
22				
23		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any	
24			statistical methods to handle missing data (eg, multiple imputation)	_19_____
25				
26				
27	Methods: Monitoring			
28				
29	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of	_NA, no DMC has
30			whether it is independent from the sponsor and competing interests; and reference to where further details	been set
31			about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not	up_____
32			needed	
33				
34		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim	_NA, no interim
35			results and make the final decision to terminate the trial	analyses are
36				performed_____
37				
38				
39	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse	_21_____
40			events and other unintended effects of trial interventions or trial conduct	
41				
42				
43				
44				
45				
46				
47				
48				
49				

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Auditing 23 Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor __NA__

Ethics and dissemination

Research ethics approval 24 Plans for seeking research ethics committee/institutional review board (REC/IRB) approval __21__

Protocol amendments 25 Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators) __21__

Consent or assent 26a Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32) __8,12__

26b Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable __NA__

Confidentiality 27 How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial __21__

Declaration of interests 28 Financial and other competing interests for principal investigators for the overall trial and each study site __24-25__

Access to data 29 Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators __21__

Ancillary and post-trial care 30 Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation __12__

Dissemination policy 31a Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions __22__

31b Authorship eligibility guidelines and any intended use of professional writers __NA – ICMJE criteria will be used__

31c Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code NA

Appendices

Informed consent materials 32 Model consent form and other related documentation given to participants and authorised surrogates Not provided in article

Biological specimens 33 Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable NA

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons [“Attribution-NonCommercial-NoDerivs 3.0 Unported”](https://creativecommons.org/licenses/by-nc-nd/3.0/) license.

For peer review only